Website

Bio

Linkin Website

Bio

Dr James Wilkie is Director of Enterprise & Innovation for the University of Birmingham, CEO for Alta Innovations (the technology transfer company for the University of Birmingham), and CEO of the Birmingham Research Park, which houses two incubators including the BioHub Birmingham®, a fully equipped life sciences incubator.

Facebook Linkin Twitter Website

Bio

After a 30-year stint as a professional editor and journalist that ended on April 30, 2016, Mr Narayanan Suresh formally joined ABLE on May 2, 2016 as its COO. The association was founded in 2003 to represent the interests of the fast-growing biotechnology industry.

For more than 13 years as the Editor of BioSpectrum, Mr N Suresh has worked closely with the biotech sector. Therefore, his rich experience and knowledge are expected to benefit the industry in due course of time. From being  a neutral observer to the biotech industry insider, his second innings now allows him to continue the association with sector.

The journalistic journey of Mr N Suresh began exactly 30 years ago in May 1996 when he joined the Times of India in New Delhi as their first-ever Exclusive Science Reporter, after a grueling 10-month training in Social Journalism with the Times Center for Media Studies( then called The Times Research Foundation School for Social Journalism) in the very first batch.

From a writer, in 1997 he moved to CyberMedia as the Associate Editor of DATAQUEST, the country’s leading IT publication, and it was a transformation, from being just a writer to an Editor-Manager. “The Chairman of Cybermedia, Mr Pradeep Gupta as well as one of its then Directors, Mr Shyam Malhotra believed in my capabilities and gave me many challenging roles that involved creating strong publication brands, says Suresh nostalgically.

At CyberMedia, he was later involved in launching and building the BioSpectrum magazine, the only source of information for biotech industry back then. Later, he also moved on with the brand to MM Activ Sci-Tech Communications when it was acquired by the later. During his long stint as the Editor, he managed and edited various publications within these publishing houses.

Linkin Website

Bio

Urvashi Prasad is a public policy specialist at NITI Aayog, the Indian Government’s premier think tank. She is also the founder of Every Voice, a platform that highlights the perspectives, needs, challenges and aspirations of people living in poverty in their own words. Urvashi was previously a Director at Operation ASHA, one of India’s largest tuberculosis control NGOs. She also led the health portfolio of the Michael & Susan Dell Foundation in India for five years. Urvashi is on the governing board of Partnership for TB Care & Control, the largest tuberculosis network in India. She completed her Bachelors in Genetics from University of Birmingham, UK, followed by a Masters in Bioscience Enterprise from University of Cambridge, UK and a Masters in Public Health from the London School of Hygiene & Tropical Medicine. Urvashi is passionate about gender-related and animal welfare issues. She is also a blogger and writes extensively for several platforms including the Huffington Post and Nextbillion.net.

Twitter Website

Bio

Andy Street, CBE (born 11 June 1963), is a British businessman and politician who was the managing director of John Lewis from 2007 to 2016. He is now the Conservative Mayor of the West Midlands, elected in the May 2017 mayoral election. As such, he is the United Kingdom’s first openly gay directly-elected metro mayor.

Linkin Website

Bio

Dr. Villoo Patell is an Academic Entrepreneur who founded Avesthagen in 1998. Avesthagen is globally recognized as a leading systems biology company with a unique model focused on the convergence of food, pharma and population genetics. A convergence that leads to continuous and path-breaking innovations in predictive, preventive, personalized healthcare. Owing to her pioneering work in the field of molecular biology, Dr. Villoo Patell has long-standing professional relationships with individuals, institutions and corporates working in the domain of biotechnology across the world. She is a key member of the Task Force and Vision Group for Biotechnology, instituted by the State Government of Karnataka and founding member of the Association of Biotechnology Led Enterprises (ABLE). Dr. Villoo Patell was Awarded the ‘Officer of the National Order of Merit’ by the President of the French Republic in April 2008.

Dr. Villoo Patell has worked with Dr. Richard Jefferson to initiate the development of pCAMBIA vectors for transformation of crops with both agrobacterium and biolistic methodologies. The pCAMBIA range of vectors, today, are used worldwide by agricultural researchers and the project was funded by the Rockefeller Foundation.
Dr. Villoo Patell has worked with Dr. Richard Jefferson in creating vectors for transformation of rice by both agrobacterium and biolistic technologies. (This was the first start to the creation of pCAMBIA vectors that went on to become used by agricultural researchers in the world.).
Funded by the Rockefeller Foundation.

Linkin Website

Bio

Brandi is the Chief Executive Officer of Seven Bridges. She previously served as Senior Vice President of  Product & Science and in that capacity led product strategy, managed the product organization, and oversaw the company’s largest scientific projects. Notably, she guided the creation of the first National Cancer Institute (NCI) Cancer Genomics Cloud pilot, which now supports the analytic needs of about 1,500 researchers investigating petabytes of genomic data collected in The Cancer Genome Atlas (TCGA).

Brandi is a co-chair and founding member of the Blood Profiling Atlas in Cancer project, which started as a part of Vice President Joe Biden’s Cancer Moonshot.  She leads the data working group, where she supports approximately 30 pharmaceutical and diagnostics companies, along with academic partners and regulators, in accelerating the development of safe, reliable, and accurate liquid biopsies.

Brandi is an active member of multiple professional organizations including the Common Workflow Language working group (since 2014), the International Cancer Genome Consortium (since 2015), the Pan Cancer Analysis of Whole Genomes project (since 2015), and the American Association for Cancer Research (since 2016).  Previously, she was an active member of the American Heart Association (2008-2010).

Prior to joining Seven Bridges, Brandi was a Postdoctoral research fellow in the Department of Stem Cell and Regenerative Biology at Harvard University, where she focused on uncovering differences in small RNA and protein coding RNA expression, splicing, and editing in purified human motor neurons derived from induced pluripotent stem cells from healthy controls or ALS patients.  As a graduate student at Tufts University, Brandi’s research helped explain the molecular mechanisms of vascular smooth muscle regulation by microRNAs, and lead to the identification of a novel post-transcriptional mode of microRNA regulation.

Brandi holds a Ph.D. in Biochemistry from Tufts Sackler School of Medicine and a B.S. in Biochemistry from the University of Rochester. Her work has been published in Nature, Cell, Molecular Cell and other leading journals.

Linkin Website

Bio

Tony Hickson BSc, MBA, CLP, RTTP is Managing Director of Imperial Innovations and an Executive Director on the board of Touchstone Innovations plc. Tony is responsible for intellectual property sourcing, licensing and spin-out creation for technologies arising from Imperial College London. Prior to joining the company in 2002, Tony had acquired 15 years of commercial and business development experience in bioscience companies including Wellcome Group, Murex Biotech, Abbott Laboratories and Kalibrant Limited.

He has been a board director or observer for a number of start-up companies including Emcision, Polytherics (now Abzena) and Catapult Therapy TCR Limited, and was instrumental in the creation of companies such as Thiakis (sold to Wyeth, now Pfizer, in 2008), Respivert (sold to J&J in 2010), Circassia (floated on LSE in 2014) and Cell Medica (in advanced clinical studies). Tony is a Certified Licensing Professional, a board director of PraxisUnico and until recently acted as Chairman of the Intellectual Property Board of the European Institute of Technology Climate Change KIC.

Website

Bio

Lars Dahle is the Founder, and has been CEO of Digno since its inception in 2012. He is a thought-leader in the use of Telehealth and Remote Patient Monitoring in Norway and is an advisor to health care policymakers in the parliament of Norway. Government agencies and LocaL Mnicipal bodies. His focus is on understanding and overcoming the organisational inhibitors of telecare providers to start and then scale up the use of Telehealth/Remote Patient Monitoring.

Before Dignio, Mr Dahle held senior management positions in Telecom operators and IT-vendors, such as HP. He holds a MS in Computer Science from the Technical University of Norway  (NTNU) and a MS in Management from MIT, Solan School of Management.

Linkin Website

Bio

Linkin Website

Bio

Professor S.S. Vasan is a Senior Business Development Manager (Research & Technical Microbiology Services & Innovation) in a new executive agency of the Department of Health, formed by the merger of Health Protection Agency with ~100 sender organisations such as National Treatment Agency, Public Health Observatories, UK National Screening Committee and NHS cancer and non-cancer screening programmes, Cancer Registries, Quality Assurance Reference Centres, Strategic Health Authorities, Specialised Commissioners, and parts of the Department of Health, including Public Health Marketing.

It aims to help bring about fundamental improvements in the public’s health and wellbeing by focusing its energies on five key priorities:

1. helping people to live longer by reducing preventable deaths from conditions such as heart disease, stroke, cancer and liver disease

2. increasing healthy life expectancy by tackling conditions which place a burden on many lives, such as anxiety, depression and back pain

3. protecting the population from infectious diseases and environmental hazards, including emerging risks and the growing problem of antimicrobial resistance

4. supporting families to give children the best start in life, through working with health visitors, Family Nurse Partnerships and the Troubled Families Programme

5. helping employers to facilitate and encourage their staff to make healthy choices.

Over the last two decades, I have gained expertise and experience in these areas:
– Biosafety, biodefence and biosecurity
– Biotechnology and bioengineerng
– GMOs, and their applications in health and agriculture
– Infectious diseases, especially medical entomology
– Microbiology services including bioprocessing and bioseparation
– New business development and innovation, especially for life sciences, bio/pharma and medical products.

Linkin e-mail Website

Bio

The Managing Director of Clonz, Narasimha is one of the key founding members of the company. His passion and vision combined with his academic and industrial experience in the world of Proteins (Proteomics) is the driving force of the company towards developing affordable bio therapeutics.

Narasimha’s Research experience in Cancer Biology at CCMB (Centre for Cellular and Molecular Biology) helped him to contribute through his work at a USA based MNC as Product Manager for its Indian subsidiary and  also as a Group Leader – Proteomics & Genomics for a reputed CRO, prior to the birth of Clonz.

His wide exposure to countries like Malaysia, Korea, Thailand, China, France, Germany, Switzerland, and USA on various business assignments is also helping in positioning the company.

Linkin Website

Bio

Salman Rahman has a career in biomedical research spanning over 25 years working at some of the UK’s leading academic and biomedical research institutions. Salman began his research career studying the biochemistry of gap junctions at the National Institute for Medical Research (MRC) using targeted antibody technology to elucidate the structure-function of connexins leading to his PhD in 1991. Following post-doctoral posts at the Thrombosis Research Institute London and at the Centre for Thrombosis and Haemostasis at St Thomas’ Hospital, where he studied the structure-function of disintegrins, Dr Rahman was appointed as Lecturer at King’s College London between 1999-2009 where he investigated the role of the extracellular matrix and disintegrin-metalloproteinase (ADAMs) in regulating vascular cell signalling in the context of angiogenesis and cardiovascular disease. His research with colleagues during this period led to discoveries that would underpin the development of Vasgen.

Dr Rahman has published over 30 papers with esteemed colleagues from the UK, US and China and holds an Honorary Senior Lectureship in the Dept. Cell Biology at the UCL Institute of Ophthalmology. In 2011, he co-founded Vasgen, where he is currently the CEO, in order to develop novel therapeutic technologies.

e-mail Website

Bio

Website

Bio

Andrew has responsibility for ensuring that processes are aligned and optimised to support the introduction and uptake of technologies and best practices. This entails creating an on going dialogue between industry and policy makers to ensure efficient and effective access and payment structures are created and maintained.

In addition to the Market Access portfolio Andrew also leads on the ABHI Ethics and Compliance program. This includes credentialing, Code of Business Practice and Human Rights.

Having graduated with a degree in Applied Physics, Andrew entered the commercial environment and has gained over 20 years experience in the medical devices industry having worked within medical technology divisions of household names such as Thorn EMI, Philips and Bristol-Myers Squibb. He has held roles covering UK and international marketing, market access and business development working with both capital and consumable equipment.

Linkin Website

Bio

Anthony Finbow has achieved success over many years as a CEO of technology businesses. Having occupied every seat at the board table: Chairman, CEO, CFO, NXD and Investor Director (for both public and private companies), he is uniquely qualified to assist Leaders and their management teams in meeting and overcoming the most significant challenges that they will encounter on their journey.

He helps Leaders across Europe by providing enlightened and creative coaching support and advice. In addition to coaching services, he provides Leadership education, training and strategy consulting services to independent businesses in the “scale up” phase, to large corporations engaged in significant change and to government.

Linkin Website

Bio

Linkin Website

Bio

Mahesh Kandula  is an entrepreneur with a proven record of founding and managing life sciences-oriented ventures from an idea into advanced clinical trials and commercialization. Inventor of several potential novel molecular entities in various therapeutic areas including Thrombosis, Lipid Disorders, Diabetes, CNS, Asthma, Cancer, Neurodegenerative Diseases, Hypertension and Liver Cirrhosis.

Sole inventor of more than 100 novel drug molecules and are currently at various stages of non-clinical and clinical development and, are also under strategic collaboration with multinationals in different geographies for advancing the lead candidates to obtain global regulatory approvals for marketing.

Experience in deal-related activities in all fields of life science businesses. Highly motivated individual with an ability for multi-tasking both individually and as part of a team.

Linkin Website

Bio

Rajlakshmi Borthakur (Raji) is the founder and CEO of TerraBlue XT, which is an award-winning healthcare startup based out of Bangalore. She has about 18 years of experience in IT and has worked at Infosys, Ernst & Young, Sapient and Virtusa before starting her own venture in 2015. She has recently won the Innovate for Digital India Challenge 1.0 that saw participation from 1900+ individuals and startups from all across India. Currently, Raji and her team of experts are working on an innovative patent-pending solution called TJay for the prediction, detection and proactive management of epilepsy.

Linkin Website

Bio

Dr. Frank Levene has more than 35 years successful experience as a UK and International CEO, NED, and an expert in facilitating investments into the USA. Holding dual nationality as a ‘ Brit ‘ and a USA citizen with residence in the USA for 25 years.  An early career built on the best practice techniques from within the fast moving consumer industry. Pioneered, built and delivered bottom-line results by cross- fertilizing multiple disciplines in consumer goods, financial services, retail, professional services, medical insurance, healthcare and PEO services.

A proven track record of profitable corporate development, led start-ups and complete restructuring. Tested across many cultures with results delivered in diverse markets such as Africa, Asia/Pacific, Russia, UK and the USA.President Director, Allianz in various markets in Asia – India, Indonesia, South Korea, and in other roles in Australia and Russia, as General Manager, Medibank, and Managing Director, Ingosstrakh. 

Within Avitus Group charged by the Chairman to help the launch Avitus in EMEA the USA enhanced offering. Targeting companies that wish to establish an investment presence in the USA. Partnered with the USA Commerce Department, Select USA in DC & EMEA, Department of International Trade, UK Export Finance, AMCHAM, BABC and multiple trade associations in general, life sciences and medical devices segments.   

 A trustee TLC a UK based hospice charity. A unique personal network of corporate, academic and government relationships.

Linkin Website

Bio

Josh Balster is the Executive Vice President at Avitus Group and has been with the company for over 13 years. Josh studied at Rocky Mountain College and proceeded to work in a fast, upscale environment at Avitus Group; first taking care of new clients, then selling their services, and most recently running the sales team as the Vice President of Sales and growing Avitus Group’s client base over 500% in the last 4 years. Avitus Group has partnerships and locations throughout the United States, as well as globally. Josh and the International Team at Avitus Group focus on assisting business owners expand their companies into the United States by covering them from all angles as they make their US entry. Josh lives in Montana and works out of the company’s Operational Headquarters in Billings, Montana.

Linkin Website

Bio

Kartik Maheshwari leads the Start-Up practice group at the multi-skilled, research based international law firm, Nishith Desai Associates (www.nishithdesai.com). He is a senior member of the Telecom – Media – Technology laws teams at NDA.Kartik is a leading attorney in various legal, tax and regulatory issues and works across cutting edge complex disruptive technologies / business models including M2M Communication, Internet of Things, smart cities, blockchain technology, privatization of space amongst others.He also has substantial experience in public policy matters and regularly works with the Department of Telecom, Department of Electronics & Information Technology, Ministry of Information and Broadcasting and the Telecom Regulatory Authority of India.He was also an integral member of the team that helped the Government of Mauritius on preparing its ‘National Innovation Framework’ and was invited by them to share his experience on using law and policy as a tool to unlock innovation at the Africa Partnership Conference, 2016.Kartik also continues to author articles and research papers on diverse legal issues which have been published by various publications.

Linkin e-mail Website

Bio

Mr. Vaibhav Parikh is an Electronics Engineer and a Lawyer. He is the Partner in-charge of the Bangalore office of the multi-skilled, research-based international law firm, Nishith Desai Associates (www.nishithdesai.com). He also heads the Technology, M&A and Private Equity practice groups. He is a member of firm’s executive committee.

He has a wide range of experience in corporate and technology transactions. He has advised several private equity and venture capital funds in their investments, specifically in e-commerce, technology, media and life sciences industry. He also has significant experience in M&A transactions including advising on one of the India’s largest e-commerce transaction.
He has been passionately involved in setting up operations and raising finance for several start-up companies. He works closely with TiE, IVCA and Nasscom to help government on startup policy.

He is actively involved in the Intellectual Property Practice and is in charge of industry focus group for IT, Telecom, and Media. He has advised many leading Indian e-commerce companies in their operations from a legal and regulatory stand point.

He has been ranked as Leading Lawyer in Mergers and Acquisitions Practice by IFLR1000 in the year  2017Asia Pacific.

He has been nominated as one of Leading Lawyer in Private Equity Practice by IFLR1000 in the year 2013. He has also been nominated as one of the world’s leading practitioners in ‘Who’s Who Legal’ for Regulatory Communications. He is recommended by Legal 500 as an expert in TMT and competition law in 2014. He has been ranked number one for TMT by Chambers and Partners in 2015.

Vaibhav Parikh is regularly sought after for his extensive experience in advising on technology matters, with an emphasis on corporate transactions.

He has authored several papers and lectured at several prestigious gatherings on a worldwide basis. He has also been acknowledged as a ‘Highly Recommended Lawyer’ for Outsourcing, and Telecom and IT and ‘Recommended Lawyer’ for Intellectual Property by the PLC Which Lawyer? 2009. He has represented NASSCOM at a WTO symposium at Geneva for presenting a paper on ‘Movement of Natural Persons’ in 2001.He is a Charter Member of TiE, Bangalore Chapter and is also on the executive council of the Franchising Association of India.

Website

Bio

Dr. BS Ajai Kumar is the chairman and CEO of HCG. Dr. Ajai Kumar founded HCG to realize his vision of making advanced cancer care accessible to all. He has been the driving force behind HCG’s growth since inception. He has served as the CEO since 2005.

Dr. Ajai Kumar’s contribution to the field of cancer care in India as well as his successes as a first generation physician entrepreneur has been widely recognized. He has been awarded the Ernst and Young Entrepreneur of the Year Award, the CII Regional Emerging Entrepreneurs Award, and the BC Roy Award by the Indian Science Monitor. He is also a recipient of the Karnataka Rajyotsava Award.

Dr. Ajai Kumar has been a practicing oncologist in the US and India for over three decades. He completed his residency training in Radiotherapy from the MD Anderson Hospital and Tumor Institute of the University of Texas, and his residency training in Oncology from the University of Virginia Hospital, Charlottesville. He received his MBBS from the St. Johns Medical College, Bangalore.

Website

Bio

Fiona has over 25 years experience in healthcare, biotechnology and venture capital. She was the co-founder and Chief Executive of the anti-infectives company Novacta Biosystems until the end of 2007. Before this Fiona was Chief Executive of Pharminox Limited, Novarticulate BV and Metris Therapeutics Limited. She worked in venture capital for Rothschilds and J&J Development Corporation in the mid-90s specialising in the strategic development and management of early-stage companies. Fiona’s early career was in business development at CRC Technology Limited and at Celltech plc.

Website

Bio

Hitesh Thakrar is a Partner of Syncona Investment Management Ltd. He is an experienced investor in the sector, having spent over 20 years investing in public global equities in the life sciences, technology and the innovation sectors.

He has worked at various institutions in equity research and Fund Management from ADIA, the sovereign wealth Fund of Abu Dhabi, JP Morgan, Aviva Group, Dresdner Bank and New Star Asset Management. He has a strong track record, rated AA manager and was also a top 1 percentile manager in global equities. He is on the Board of Desktop Genetics, a CRISPR IP library company, backed by Illumina and is an angel investor in early stage Innovation companies. He is also on the Investment Committee of the LBA Scale Up Innovation Fund.

Hitesh holds a degree in Chemistry from Kings College, London, MBA from Cranfield University and CFA, the American Association of Investment Analysts.

Linkin Website

Bio

In charge of Quantumzyme’s science and strategy, Naveen comes with over 20 years of scientific & entrepreneurial experience in the drug discovery industry across the USA, Australia and India.

He has published several research papers and the most notable was published in Nature in July 2017 with a few more interesting discoveries in the pipeline for the year.

Naveen is an entrepreneur and hands-on executive officer with extensive knowledge of Pharma, Healthcare, regulatory and medical devices scenario in India. Solid Healthcare, Life Sciences background known for strategic and focused approach, with extensive accolades for establishing creative strategies for optimizing internal operations, financial returns, limiting risk, creating lean teams, and external customer service and output.

Prior to founding Quantumzyme, he served as the CEO of Cryo Stemcell and prior to that as Director at Philips Research, where he was associated with a portfolio of opportunities for new business creation in healthcare and energy. In his previous roles, he has risen through the ranks – from being a bench worker at an Australian research institute to heading the strategic business unit of an American drug discovery informatics company. He has conceptualized and developed novel solutions for accelerating drug discovery and directed teams consisting of experts from different domains including chemistry, proteomics and systems biology. He has been instrumental in conceiving new ideas that are the basis for the company’s patent portfolio.

Has been a speaker and presenter in several international conferences.

• World Congress for Preventive and Regenerative Medicine, Taiwan.
• ABLE Bioinvest
• Bangalore Bio
• Bio Partnering Europe, London, UK.
• Bio North America, Vancouver, Canada.
• Beyond Genome Conference, San Diego, USA.
• IBM High Performance Computing conference, Hyderabad, India

Guest Lectures in several institutions like:

• IIT Madras
• University of Virginia
• University of California, San Diego
• Indian Business Academy, Bangalore, INDIA

Advisor – Board of Studies at:

• Welingkar Institute of Management
• Department of Biotechnology, SDM Group of Institutions

Previous engagements:

CEO – Cryo Stemcell

Overview of the profile:

Turnaround of the company from a Stem cell banking service provider to become a healthcare company and developed the roadmap and business plan for next level funding. Initiated PRP therapy and Hospital partnerships with new customer acquisition and sales team mobilization pan India.

Director – Philips Research Asia

Overview of the profile:

As Director Business Development at Philips Research Asia, Naveen was involved in identifying and developing technology ventures for spin-ups, spin-ins (technology acquisition) and spin-outs in Philips. He has successfully developed and managed a portfolio of opportunities for New Business Creation across Healthcare and Energy relevant for India, emerging markets and globally.

CEO – Polyclone Bioservices

Overview of the profile:

Founded Polyclone and lead the company as a CEO and successfully forged Drug Discovery Alliances, developed markets for Genomics and Proteomics services, Virtual Screening and Research Information Systems.

• Responsible for developing a Govt. recognized R&D unit
•  Successfully raised R&D Grants from various national and international agencies
•  Managing research projects from start to finish in various areas of cancer genomics
•  Filing of the first patent for a cancer target

Principal Consultant, Life Science – SysArris Inc, USA

Overview of the profile:

Initiated and implemented Bioinformatics services for SysArris. Established niche offerings and positioned the company as a leading provider of consulting, technology, outsourcing and applied research services for pharma and biotech industry.

RESEARCH

CRC for Diagnostics Technologies (CDT) Brisbane, Australia Summary:

CDT is an A$40 million/yr. Co operative research center and a consortium of academic partners and members of Australian Diagnostics Manufacturers Association, sited at Brisbane. This Project involved developing a novel Polymerase Chain Reaction (PCR) based DNA diagnostic assay, utilizing the Amplification Refractory Mutation System (ARMS) principle for the detection of single gene mutations.

EDUCATION

MSc, Applied Science (Life Science) Queensland University of Technology, Brisbane, AUSTRALIA BSc, Microbiology, Bangalore University, INDIA

Linkin Twitter Website

Bio

Prabhu Mishra , CEO & Founder- StemGenn Therapeutics, President – StemMax Research & Therapeutics Pvt Ltd. Co-Founder- Global StemGenn Therapy & Research PVT ltd. Ex- Secretary General – Stem cell society (India) , Founder President – Anti ageing Foundation, Vice President- Indian Stem cell study Group.

Advisor: Regenerative Therapy- IORA, Stem cell committee Head – ISAR Delhi Chapter , Reviewer – Journal of cutaneous and aesthetic surgery. Associate Editor – Indian journal of stem cell Therapy. Collaborator with SumanDeep Vidyapeeth University , InDNA LIFESCIENCES. Member ,International society of Cellular Therapy, American society of cell and Gene Therapy, International society of stem cell Research. Founded- Indian Regenerative and Aesthetic science study group.

Given consultation to more than 15 stem cell facilities. Prabhu Mishra have set up 8 stem cells centre across country and Internationally.

Prabhu Mishra, welcomes you to StemGenn Therapeutics, a leading stem cell therapy & regenerative medicine services company, hurling the stem cell revolution in India. It is dedicated to the development and commercialisation of cellular therapies and stem cell research in India. Prabhu Mishra works to develop strategic alliances and to implement national and international projects for the mission of advancing regenerative medicine and stem cell therapy.

StemGenn Mission is contribute to human health by enabling technologies using Regenerative Medicine. Aims to provide treatment option in Aesthetic Medicine, Anti Ageing , Infertility, Cosmetic Gynaecology , Wellness , Life style Diseases & Auto immune diseases.

StemGenn started world class training module in Stem Cell & Regenerative Medicine , Bio Identical Hormones , Aesthetic Medicine , Cosmetic Gynaecology & Anti Ageing .

Prabhu Mishra works to develop strategic alliances and to implement national and international projects for the mission of advancing regenerative medicine and stem cell therapy. Prabhu’s personal experience with life-changing cellular therapies and adult stem cell transplant programme ignited his passion to be involved with an innovative new area of medicine bringing together the industry leaders in regulatory, science, medicine, safety and ethics via a association model to yield the best possible patient outcomes.
 Prabhu participates in the organizational business strategy, membership procurement, marketing, international and domestic conference and event planning/implementation, financial decisions and budgeting. Prabhu works with the GIOSTAR team to develop compelling business plans to optimize strategy, present a competitive edge, and to articulate the client’s competitive position. Prabhu creates financial reports for Executive Summaries such as profit/loss statements which include sales forecasts, personnel and operating costs, break even analysis and cash flow projections.

Specialties Area: Blood Bank & Transfusion Medicine , Cord blood Banking, Stem cells (adipose, dental pulp, peripheral blood, limbal) Plastic Surgery, General Surgery(Abdominal Wall Reconstruction, Hernia Repair, Breast Surgery, Wound Care and Trauma), Orthopedics, Spine , Sports Medicine, Neurosurgery, Trauma, Colon Rectal, Cardiac, Perfusion, Dental, Oral Max , Vascular, BMA, Bone Marrow Aspirate, PRP, Platelet Rich Plasma, Stem Cell, Tissue Regeneration and Regenerative Medicine.

Linkin Twitter Website

Bio

Phillip D’Costa is an experienced Partner specialising in commercial, fraud, IT and financial services dispute resolution, arbitration and ADR. Phillip has been ranked as a leading individual for UK and India dispute resolution in Chambers Global 2014 and foreign expert in Chambers Global 2015.

Key areas of practice:
• Commercial – Litigation & Arbitration, jurisdictional issues, partnership/LLP, contractual claims, shareholders, Technology, director’s duties and insolvency;
• Civil Fraud – Company investigations, restitution claims, misrepresentation, asset tracing, freezing & recovery, supply chain fraud, employee fraud;
• Financial Services & Regulatory – Securitisation, asset finance, leasing, share fraud, miss-selling, derivatives and structured products, money laundering, regulatory, compliance;• Has a particular interest in arbitration and transactional work involving India and has advised on a number of disputes and transactions involving India or Indian Companies, Families and Individuals.

Specialities:
Civil Fraud – Company investigations, Freezing Orders, Fraud investigation and Asset tracing.

Commercial – Litigation & International arbitration, jurisdictional issues, partnership and LLP advice and disputes, IT & IP disputes, contractual claims, shareholders disputes, Asset Finance & Leasing, Cross border transactions, Insolvency and Licensing.

Financial Services & Regulatory – miss-selling, money laundering, regulatory, compliance.

Linkin Website

Bio

Shobha Vijayaraghavan has 20 years of business experience in Life Sciences – Identifying, building and monetizing value in the organization: from ideas to products to platforms.

Her experience and expertise include:

* Seamless and continuous integration of information and analysis of the market and clinic with in-house scientific knowledge to enhance research programs and product propositions.

* Deal-making, out-licensing and collaboration experience with large pharma and research organizations – benchmark deals with above average terms

* Valuation and value building, including strategizing for growth and funding.

* Portfolio assessment, prioritization and planning, based on intensive analysis of market and clinic as well as a thorough understanding of the strengths, differentiation and gaps in the portfolio.

Website

Bio

Andrew Fried is IBM Life Sciences Leader for Europe.

Andrew helps clients address industry imperatives and save lives through the power of cognitive insights.  He works with clients to advance the next generation of discovery and development, acting on insights to drive value, enhance relationships across the ecosystem and empowering people to make better decisions.

Prior to transferring to Europe in July 2015, Andrew was IBM’s Life Sciences Leader for China. While in China Andrew worked with many leading multi-national companies and several Chinese Life Sciences companies who were leaders in their respective segment.

Before joining IBM in 2000, Andrew had a successful 14-year career with a leading strategy consulting company.  He graduated from Melbourne University with a Bachelor of Arts, and Monash University (Melbourne, Australia) with a Bachelor of Business.  Andrew has a Masters of Business Administration from the International University of Japan and is a Fellow of the Financial Services Institute of Australasia. He was a three-term board member on a government enterprise with assets of over $350M. He was a founding director of a successful dot.com start-up in the early 2000s.

Andrew is an advocate of sport and fitness as a gateway to good health.  He is passionate about the role of genomics in identifying both the cause of disease and personalized solutions.

Website

Bio

Dr. Aman Puri assumed charge as Consul General of India, Birmingham on 22 February, 2017. He is a member of the Indian Foreign Service, having joined the service in 2003. He served at the Indian Mission to the European Union, Belgium and Luxembourg, based at Brussels, from 2005-08. He served at the Passport Office in Chandigarh for little over a year from 2009-10.

Subsequently, he held the office of Deputy Chief of the Protocol (Ceremonial) from 2010-2013, and his responsibilities included organising the foreign visits of Prime Minister of India, and the incoming visits at the level of Heads of States/Heads of Government, Vice Presidents and Foreign Ministers.

Dr. Puri was the Regional Passport Officer, New Delhi from 2013-16, during which period many citizen centric measures were implemented by the Ministry of External Affairs.

Most recently, he had brief stints as Director in the Multi-lateral Economic Relations Division, followed by the Northern Division of the Ministry of External Affairs. The Northern Division deals with India’s relations with Nepal and Bhutan.

Dr. Puri (born 1976) did his schooling from St. John’s High School, Chandigarh, and qualified as Dentist from Dental College based at Amritsar.

Website

Bio

Dr. Vishwas is a molecular virologist with over 18 yrs experience in bio/pharmaceutical discovery research at leading Indian pharmaceutical companies. He was associated with the discovery & pre-clinical development of 2 NCEs and also helped establish the protein therapeutics research center of Glenmark Pharmaceuticals at Neuchatel, Switzerland. Dr. Vishwas has concieved & developed the eSAME technology platform of Seagull BioSolutions.

e-mail Website

Bio

Theodoros N. Arvanitis is a Professor of e-Health Innovation and Head of Research at the Institute of Digital Healthcare, WMG, at University of Warwick. He also holds the post of co-Director of the West Midlands AHSN Digital Theme. He received his RT (BSc) degree (medical radiological technology) in 1990, from the Technological Educational Institute of Athens, Greece, and his DPhil (biomedical engineering) in 1997 from the University of Sussex, UK. His postdoctoral work at the University of Sussex included a lab director/research fellow post at the Trafford Centre for Medical Research (1995) and a full-time lectureship in the School of Cognitive and Computer Sciences (1995-1998). In 1998, he joined the School of Electronic, Electrical & Computer Engineering, University of Birmingham, UK, as a full-time Lecturer (1998-2003), Senior Lecturer (2003-2007) and subsequently Reader in Biomedical Informatics, Signals and Systems (2007-2013). His research interests span the areas of biomedical engineering, neuroimaging and health informatics.

Professor Arvanitis has a substantial academic publication record (h-index= 24 with a total of 1727 citations @ scholar google, 1 Book; 4 Book Chapters; 2 Patent filings; 81 full papers in refereed journals; 28 abstracts in refereed journals; 165 publications in refereed conference proceedings, 58 publications/keynote talks at un-refereed conferences and events, 11 guest editorials in journals, 21 published research reports and newsletters), while he has received research funding from national (UK), European and international governmental funding agencies, charities and industry. Theo has been involved in UK (BSI) and EU (CEN) standardisation work, while he has recently contributed work in various working groups of the US National Cancer Institute Cancer Biomedical Informatics Grid (CaBIG) effort. He is a Charted Engineer (CEng), Fellow of the Royal Society of Medicine (FRSM and a member of various scientific and professional groups (IET, AMIA, NYAS, RCS, ISMRM). He recently took the role of Joint Editor-in-Chief at the Digital Health open access peer-reviewed journal, published by Sage Publications, UK.

Linkin e-mail Website

Bio

Manish is responsible for providing a strategic vision to NSDC in ensuring that the team moves cohesively in one direction towards achievement of the Prime Minister’s Skill India Mission. Manish also represents NSDC at domestic and international fora. He is also the official spokesperson for NSDC.

Linkin Website

Bio

Raghav is a strategic, execution focused and entrepreneurial business leader, with proven track record in the consumer, internet and management consulting industries in India, south-east Asia and Europe. Have led three consumer internet businesses in India – Coursera, BlaBlaCar and Sucré Patisserie – and successfully created new spaces in the consumer domain. Have over 19 years of experience across Coursera, BlaBlaCar, Sucré Patisserie, Booz & Co and Technopak Advisors.

Website

Bio

Linkin Twitter e-mail Website

Bio

Francisco Marmolejo is the World Bank’s Lead Tertiary Education Specialist and Coordinator of its Network of Higher Education Specialists. He serves as the coordinator of the internal thematic group on higher education, which helps facilitate the exchange of ideas on higher education initiatives across the globe.

Previously, he served as founding Executive Director of the Consortium for North American Higher Education Collaboration (CONAHEC), a network of more than 160 higher education institutions primarily from Canada, the U.S. and Mexico, based at the University of Arizona (UA), where he also worked as Assistant Vice President.

At UA, he was Affiliated Researcher at the Center for the Study of Higher Education and Affiliate Faculty at the Center for Latin American Studies.

Linkin e-mail Website

Bio

Nathan Andrews believes in Working to deliver on the brand promise to all stakeholders while ensuring customer delight as well as the financial success of every business within the city. To make Lavasa India’s first hill city the preferred destination for residents, students and tourists. A city of learning, art and culture with a quality of life unparalleled in the country.

Linkin e-mail Website

Bio

Linkin e-mail Website

Bio

Professor Mammo Muchie holds a DPhil in Science, Technology, and Innovation for Development (STI&D) from the University of Sussex. UK. He is currently a DST/NRF rated Research Professor at the Faculty of Management Sciences, Tshwane University of Technology, South Africa. He is a fellow of the South African Academy of Sciences and the African Academy of Sciences. He is also currently adjunct Professor at the Adama Science, Technology University, Arsi University, Addis Ababa University and University of Gondar, Ethiopia. He has been senior research associate at the SPMTDC programme and also has become Senior Research Associate at the TMD Centre of Oxford University.

He is collaborating with researchers (DILIC) on the potential research areas of Africa-China industrial high-technology sectors. He has been invited as Associate Faculty professor at Sussex University, UK for the next three years; at the University of Economics in Prague as visiting professor, Jawarahal Nehru University India, Tonji and Shanghai University, China; Honorary Professor Jiaxing University, China, Assistant Professor Amsterdam University, Visiting Professor Carleton College, USA; Principal Lecturer, Middlesex University, Professor, Aalborg University; Part–time Lecturer, Cambridge University; Honorary Professor UNISA. Professor Mammo held various positions globally, including the Director of the Research Programme on Civil Society and African Integration at the then University of Kwa Zulu-Natal; board member at the North Western University, Chengdu, China.

He is currently the chairman of the advisory board of African Talent hub of the Community Interest Company (registration no.10461990) to raise funds for making Africa the talent, innovation, entrepreneurship, creativity and knowledge hub of the world. He has been appointed as special distinguished advisor to the Africa Union’s Student Council and a mentor for the African Entrepreneurship award. He has initiated the African Unity for Renaissance and Knowledge Exchange series of conferences since the last six years. He is a founding scientific advisor to ´the African Solar network, founding chairman of the Network of Ethiopian scholars. He has lead the SIDA, Sweden funded research on engineering design and on transformative innovation for African integrated development and educate on public media to speed up the creation of innovative and renascent Africa. He is also a co-founding member of the Nano Technology Institute in TUT leading the innovation side of the research.

e-mail Website

Bio

Souvik Bhattacharyya graduated from Jadavpur University, Kolkata with a Bachelor’s degree (1981), MS (1985) from University of Cincinnati, USA and PhD from Texas A&M University (1991), USA – all in Mechanical Engineering specializing in thermal sciences. After a post-doctoral research stint at TexasA&M, he joined the faculty of IIT Kharagpur in 1991 where he was Dean (Students’ Affairs) during 2009-2012 and has been a Professor of Mechanical Engineering since 2003, Professor (HAG) since 2009. He also held faculty position at University of Canterbury, Christchurch, New Zealand during 1998-2000. He served as the Vice-Chancellor of Jadavpur University, Kolkata during August 2012–October 2013 and as Deputy Director of IIT Kharagpur during 2013-2016. Currently he is the Vice-Chancellor of BITS Pilani. Prof Bhattacharyya is a Member of the Research Council of CSIR-CGCRI, the General Council & Executive Board of ISM, Dhanbad and the Civil & Mechanical Engineering Project Advisory Committee (PAC) of SERB, DST.

 Dr Bhattacharyya has been on the Editorial Boards of International Journal of Power and Energy Systems and Journal of Nano Energy and Power Research. He is an Associate Editor of the international journal Alternative Energy and was on the Editorial Board of Energy Conversion and Management during 2007-2013. He was a member of the Committee on Fast track scheme for young scientists, DST during 2007 –2012. His research interests include heat transfer enhancement, thermodynamic optimization, energy engineering, natural refrigerant based transcritical heating-cooling systems, and natural circulation loops. A recipient of ASHRAE Best Paper Award, Dr Bhattacharyya has published about 220 research articles in indexed international journals and conference proceedings and is a co-author of the celebrated Heat Transfer text with J P Holman. 

He is a Fellow of the Indian National Academy of Engineering (INAE), National Academy of Science, India (NASI) and WB Academy of Science & Technology.

He is known as an adored teacher among the students of IIT Kharagpur and was the first recipient of the Outstanding Teacher Award of Indian National Academy of Engineering in its inaugural year in 2013.

Linkin e-mail Website

Bio

Kishore Balaji has been working across multiple verticals, in many roles helping organisations build their strategies & businesses.

The spaces he has been engaged in so far ranged between Education, Training, Employability, Rural Dev, ICT for SMBs/ SMEs, Entrepreneurship & Innovation, Nation Building projects among others, acorss South Asia and APAC.

Linkin e-mail Website

Bio

Dr. Chandra Bhushan Sharma, the present Chairman of the National Institute of Open Schooling (NIOS), is Professor of Education at the School of Education, Indira Gandhi National Open University, New Delhi.

He has taught for three decades and sat on many national committees and commissions constituted to advise governments and institutions. His expertise is in policy making from school to higher education especially distance mode education. He was one of the three member committee constituted by the Government of India to draft the Distance Education Council of India Bill. He has also been on the committee to suggest revamping of teacher education in India.

Linkin e-mail Website

Bio

Pranjal lead venture capital investments, champion portfolio management in investee companies, and drive strategic projects for Bertelsmann Group companies in India. He has been part of A.T. Kearney India unit leadership, driving business development & project delivery in Communication, Media & Technology practice. Pranjal has expertise in shaping growth strategy and its operationalization, and in driving large-scale operational excellence programs for CXOs primarily in telecoms, retail, consumer goods and auto sector.

Linkin Twitter e-mail Website

Bio

Dr. Ganesh has set up 5F World (www.5FWorld.com) as a meta start-up which scans the start-up eco-system and makes investments in select start-ups that transform employee and customer journeys. He is Executive Chairman of 5F World and also Chairman of two incubated firms, Global Talent Track and Skills Alpha.

Dr. Ganesh is a Senior Advisor for Digital Transformation with McKinsey & Co and the Pune Smart City Initiative and is currently leading the development of a Start-Up Hub in the city of Pune which will provide research to city investors and established firms and also support the mentoring and corporate linkages of start-ups anywhere which need to establish linkages with industry leaders in the Manufacturing, Financial Services, Information Technology and Business Process Management sectors of India. He is also advising start-ups in the USA Singapore and India which are focused on Digital Financial Services and Retail Commerce.

Linkin Website

Bio

Marius Westhoff has more than 6 years experience across Corporate, Venture Capital & StartUp in Education & Digital Media across Europe, US and India. In charge of P&L for Verticals / Member of Founding Team to grow the venture and build careers of tomorrow.

Linkin e-mail Website

Bio

Anand Sudarshan is the Founder & Director of Sylvant Advisors Private Limited. Anand is also an independent director at NIIT. Till June 2012, he was Vice-Chairman & Managing Director of MaGE, where he has had a distinguished career since May 2006.

He currently advises companies & entities in the education sector, and is also a fund advisor with TVS Capital Funds. He is active in supporting Government of India in policy formulation, and is a member of select Committees & Task Forces of the Planning Commission of India as well as the Ministry of Human Resource Development.

Linkin Twitter e-mail Website

Bio

Poonam Heryani is the Head of Academics, ASPAM Indian International School, Sharjah. She is a much sought after speaker and trainer, she has led and conducted numerous workshops for school educators in India and the Middle East.

Having completed her MSED Research in Teacher Leadership from Richard Riley College of Education, Walden University, USA, currently Poonam’s area of interest is “How leadership practices in a school can impact the learning and achievement of students”.

Poonam provides Instructional leadership and teacher training, supports curriculum design that addresses what students must know factually, understand conceptually and be able to do in skills and processes, she addresses critical issues of improving instruction that develops conceptual thinking along with critical, creative and reflective thinking.

Having spent twenty eight years as an educator, Principal and school administrator, Poonam Heryani has become widely recognised as an ambassador for progressive education with a focus on designing and delivering curriculum, practices pertaining to curriculum reform, instructional strategies that encourage critical thinking and strategic planning.

Linkin Website

Bio

Bio

Professor Sir Malcolm Grant , CBE, FAcSS  is the Chairman of NHS England, formerly known as the NHS Commissioning Board. He is also a barrister and academic lawyer.

Grant was appointed as chair of the newly formed NHS Commissioning Board in 2011 by the Secretary of State for Health, Andrew Lansley. He was previously the ninth President and Provost of University College London – the head as well as principal academic and administrative officer of the university – for over a decade from 2003 until 2013. He is the current Chancellor of the University of York.

In August 2003, Grant left the University of Cambridge to become Provost and President of University College London.

In 2004, Grant launched ‘The Campaign for UCL’. The campaign was designed to generate 300 million pounds of extra funding for the university, to expand facilities and provide for new research initiatives. The appeal will also fund an ear institute, a spinal repair unit and an institute for women’s health. Fifty million pounds of the targeted funds will provide support for students, in the form of bursaries, scholarships, and post-doctoral fellowships. It was the biggest ever fundraising target set by a university in the United Kingdom, until Cambridge set a £1 billion target for its 800-year anniversary followed by the highest ever £3 billion target set by University of Oxford through the Oxford thinking campaign.

Grant said of the ‘Campaign’:

“I have heard it suggested that the concept of philanthropy is somehow alien to the national psyche, and that asking for money is not the British thing to do. This is, frankly, nonsense. Most of our leading universities owe their origins to philanthropy. Without the generosity of our founding fathers, UCL would never have seen the light of day back in 1826. This campaign will enable UCL, a real British success story, to enjoy the kind of resources to enable us to compete with the world’s very best academic institutions”

— Interview with BBC News, 2004

In 2005, on an invitation from The Cheese Grater, he agreed to shave off his moustache if UCL students raised £1500 for Comic Relief, on Red Nose Day. Unfortunately for his moustache — of 33 years — students and staff duly donated over £2,000. However, it has since regrown.

In 2006, he spoke out against the Israel university boycotts by the Association of University Lecturers (now the Universities Colleges Union). In 2006, Grant also controversially stated that European students had better English skills than many British students.

In 2007, Grant said the achievement and academic gap between male and female students was widening. Since 1998, 313,259 more women than men have made university applications. Malcolm Grant said, “the trend indicated a big fall in the number of university-educated men”.

In January 2007, he argued that the entire nationwide university approach to funding needed a different approach. In regard to UCL’s need for additional funding, he stated the reasons in an interview with the BBC:

“”To provide world-class research – through discovery, invention and creativity – and to convey the excitement of it to able young minds.”

— Interview with BBC News, 2007

In June 2007, in response to legal threats from Alan Lakin, husband of a purveyor of herbal remedies, Grant required Professor David Colquhoun to remove his website, “Improbable Science” from university computers. An outcry from the scientific community ensued, and Grant reconsidered, inviting Dr. Colquhoun to bring the site back to UCL once it had been edited for libel.

In December 2011, Grant became the first UCL Provost to be challenged by ‘a vote of No Confidence’ by UCL Union, the representative body of UCL students, following his appointment as chair of the NHS Commissioning Board. However this was deemed unconstitutional.^{[citation needed]} As a result, the matter was passed to a referendum in which the students of UCL voted in confidence of Grant by 1699 votes to 1185, with 391 abstentions.

Linkin Twitter e-mail Website

Bio

Andreas Schleicher is Director for Education and Skills, and Special Advisor on Education Policy to the Secretary-General at the Organisation for Economic Co-operation and Development (OECD) in Paris.

As a key member of the OECD Senior Management team, Mr. Schleicher supports the Secretary-General’s strategy to produce analysis and policy advice that advances economic growth and social progress. He promotes the work of the Directorate for Education and Skills on a global stage and fosters co-operation both within and outside the OECD. In addition to policy and country reviews, the work of the Directorate includes the Programme for International Student Assessment (PISA), the OECD Survey of Adult Skills (PIAAC), the OECD Teaching and Learning International Survey (TALIS), and the development and analysis of benchmarks on the performance of education systems (INES).

Before joining the OECD, Mr. Schleicher was Director for Analysis at the International Association for Educational Achievement (IEA). He studied Physics in Germany and received a degree in Mathematics and Statistics in Australia. He is the recipient of numerous honours and awards, including the “Theodor Heuss” prize, awarded in the name of the first president of the Federal Republic of Germany for “exemplary democratic engagement”. He holds an honorary Professorship at the University of Heidelberg.

Linkin e-mail Website

Bio

Justin van Fleet is also the Chief of Staff to the United Nations Special Envoy for Global Education, Former UK Prime Minister Gordon Brown. He serves on the Advisory Board of the Global Business Coalition for Education and works with the UK children’s charity, Theirworld, founded by Sarah Brown.

He was previously a fellow at the Brookings Institution’s Center for Universal Education in Washington, D.C. where his research focused on corporate social investments and philanthropy for global education. He graduated with a PhD from the University of Maryland in international education policy and holds a Master’s degree from Harvard University in the same field.

Linkin Twitter e-mail Website

Bio

Throughout her career, Dr Mary Stiasny has worked tirelessly to both deliver and promote quality accessible education across the world.

Prior to becoming Pro Vice-Chancellor (International), Dr Stiasny provided strategic direction and leadership at the Institute of Education, in her capacity as Pro-Director with responsibility for Learning, Teaching and International.

Working life for Dr Stiasny began as a secondary school teacher in West London. She then joined Goldsmiths College, where she was involved in initial teacher education, becoming Director of PGCE and Deputy Head of the Department of Educational Studies. This was followed by a move to Oxford Brookes University, where she was appointed Deputy Head of the School of Education. She then returned to London, to become Head of the School of Education and Training at the University of Greenwich. Following this, she spent four years at the British Council as Director of Education and Training before joining the Institute of Education.

Dr Stiasny’s practical and strategic experience in education spans across a wide range of roles, including providing consultancy for a number of educational projects that have attracted external funding, and as an external examiner.

Linkin Website

Bio

Dr. Stephen Minger research has been at the forefront of human stem cell research. His group was the first to deposit a human ES cell line into the UK Stem Cell Bank and first to pursue Somatic Cell Nuclear Transfer (SCNT) to generate “hybrid human embryos” for research. Besides research, Stephen has been actively involved with the UK government helping legislate the first Human Embryo Bill in 2009 and being the Stem Cell Expert and Member of the UK Gene Therapy Advisory Committee (GTAC) at the Department of Health from 2006-2012 helping also the Chinese government with Stem Cell legislature.

In 2009 he was appointed first the Global Director for Research and Development for Cell Therapies at GE Healthcare. In 2013 he was appointed Chief Scientist for Cellular Sciences to lead their research for technology development within cellular therapies and diagnostics. He is a member of the Board of Directors of the Canadian Centre for the Commercialisation of Regenerative Medicine (CCRM) and Scientific Advisor for BioLamina. He also serves as the Director of SLM Blue Skies Innovations Ltd, providing expert analysis in emerging healthcare technologies for the life sciences investment community.

Website

Bio

Patricia Hewitt is the Chair of the UK India Business Council (UKIBC), the premier business-to-business network that works with the British Government to promote bilateral trade between the UK and India.

Patricia Hewitt had a long and distinguished career in politics and government, including as the longest-serving Secretary of State for Trade and Industry in the last fifty years. In that role, she made India her top international priority, believing – as she said in 2002 – that India was rapidly becoming ‘the world’s most exciting knowledge-driven economy’. She also served in Tony Blair’s government as Cabinet Minister for Women (2001 – 2005) and Secretary of State for Health (2005 – 2007). Between 1997 and 2010, Patricia was Labour MP for Leicester West and continues to have close ties with the city and its large British Asian community.

Patricia is a non-executive director of EuroTunnel, a member of the International Advisory Board of Sutherland Global Services and a senior adviser to FTI Consulting. She was for many years Senior Independent Director of BT, where she chaired the remuneration and pensions committees, and a member of the UK government’s Asia Task Force. She is also a member of the UK India Round Table.

For the last six years, Patricia has been an active supporter of Katha, a ‘profit for all’ social enterprise that is transforming the lives of children and their families in Delhi’s slums. She chairs the donor consortium established by the British Asian Trust – one of the Prince of Wales’s Trusts – to support Katha’s work.

In October 2014, Patricia was selected by the British Government to receive the first Dadabhai Naoroji award to recognise her contribution to economic ties between the UK and India.

Born in Australia, Patricia took her undergraduate degree at Cambridge University, and has been awarded an MA by both Cambridge and Oxford. She is an Honorary Associate of Newnham College, Cambridge, an Honorary Doctor of De Montfort University and an Honorary Fellow of the London Business School.

Patricia’s husband, William Birtles, has recently retired from a long career as a barrister and senior judge at the Mayor’s and City of London Court. They have a daughter and a son, both in their 20’s. In her spare time, Patricia enjoys reading, music, theatre and gardening. Although her efforts to learn Hindi have not been very successful, she wowed the Vibrant Gujarat summit in January 2013 with her speech in Gujarati!

Linkin e-mail Website

Bio

Pramath Raj Sinha is a Senior Advisor of the Albright Stonebridge Group, India and the Founder and Managing Director of 9.9 Mediaworx Private Limited. Prior to founding 9.9 Media, he was a Partner at Mckinsey and led the ABP Group, one of India’s leading and most diversified media conglomerates.

Pramath helped set up and served as the Founding Dean of the Indian School of Business (ISB). He continues to be a member of its Board of Governors.

Pramath is a Director on the Boards of PRADAN, India’s leading development institution focused on improving livelihoods in the country’s poorest district and of the Central Square Foundation, a philanthropic fund focused on improving the educational outcomes for low-income children in India. He holds a Bachelors degree from IIT Kanpur and an MSE and PhD from University of Pennsylvania.

Website

Bio

Mr. Francis Joseph has more than 20 years of Management experience in School Education; in areas that include School Operations, Human Resource, Technology, Organizational Development and Strategy Planning.

He has extensively worked in establishing and managing schools for one of India’s Largest Singly owned/managed & non-franchised Educational group as its COO in India & Middle East (till year 2011), from where he started as a Teacher in year 1993. He was also instrumental in developing many technological initiatives and revolutionary practices in Schools, both in India and abroad. Francis is also a recipient of the “Limca Book of Record” (Edition 2013) for managing the fastest School admission process (10 days) in the country; which was also appreciated by the HRD Minister of State, Government of India and then Chief Minister of Gujarat, Shri. Narendra Modi.

Francis Joseph has established and operated several prestigious schools in India and Middle East; pursuing curricula of Indian and International Boards. Francis was also selected as an emerging edupreneur in India (year 2013) for an incubator programme conducted by the Pearson Affordable Learning Fund (U.K.) for his efforts in affordable and low-cost education in smaller towns and villages. Francis is also associated with the Archdiocesan Board of Education (Mumbai) and CfBT India in their school development projects. Francis is the Vice-President of Early Childhood Association (India), a private NGO in early childhood care and education with members from all across the country. His core strengths are high-level networking, communication skills, people management, technology enabler, service oriented, grass-root level experience in establishing schools and developing strategy related to perception building, marketing and scalability.

Linkin Website

Bio

Pratik Dattani is the Managing Director at EPG Economic and Strategy Consulting and UK Director for FICCI. He is also the co-founder of a tech start-up in the CSR space. Previously he worked in Economic Consulting at FTI Consulting, on public policy and international arbitration cases, and at Deloitte in London and Abu Dhabi, focussing on public policy and telecoms. In 2009, he founded and led one of the Deloitte’s largest diversity networks. He was Chairman for a not-for-profit membership organisation with several thousand members for three years.He studied Economics at Warwick University, where he was awarded the Prize for Excellence, and LMU University of Munich. Pratik’s dissertation won a prize at an international economics conference at Georgetown University, Washington DC. He has published academic research on behavioural economics and social impact, most recently in the Social Enterprise Journal in 2014. He is a regular commentator on public policy and India across print, TV and online media.

Linkin Website

Bio

Harriet  Fear joined One Nucleus (formerly ERBI) as CEO in February 2009. She previously worked as a Diplomat with the British Foreign Office for 21 years serving in over 17 countries around the globe. Half her career was spent in the commercial field, latterly heading UK Trade & Investments national life sciences trade team for over 5 years.

She was attracted to the role at One Nucleus because she wanted to spend time helping companies maximise their competitiveness and to lead a team which already had an excellent reputation. Since her arrival at One Nucleus, the company has redefined its membership (now life science and healthcare, not only biotech), formed strong and strategic relations with like minded US counterparts for the benefit of members and merged ERBI with London Biotechnology Network to enhance the offer to members and create a stronger critical mass on the international stage.

One Nucleus is the largest membership organisation in Europe. A not-for-profit private company, it has over 450 members including pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial service providers.

The One Nucleus mission is to maximise the global competitiveness of its members. For their science and technology-based members, this means being global leaders in the research, development and commercialisation of healthcare innovations that radically improve the quality of people’s lives around the world. For their business and professional services members, it means delivering exceptional services that significantly enhance the business performance of their clients.

Harriet Fear has accepted the Prime Ministers invitation to continue in her UK Business Ambassador role for a further two years to 2017. She continues to be Chief Executive of One Nucleus – her first priority and passion. By accepting this invitation, Harriet has agreed to undertake, in the margins of her personal or business travel, a programme of activities developed by and with the Government until July 2017. This could include for example, hosting a reception in a country she is travelling to in order to highlight UK expertise in the life science and healthcare sector, briefing UK Ministers and HM Ambassadors on key business priorities and interests as they might arise; meeting overseas Ministers and inward missions; and providing insights into how UK Trade & Investment can better deliver for business.

Linkin Twitter e-mail Website

Bio

Lord Karan Bilimoria CBE, DL is the founder of Cobra Beer, Chairman of the Cobra Beer Partnership Limited and of Molson Coors Cobra India, both joint ventures with the global brewing company, Molson Coors.

He is the Founding Chairman of the UK India Business Council, a Deputy Lieutenant of Greater London, a former Chancellor of Thames Valley University (now the University of West London); he was the youngest University Chancellor in the UK when appointed.

In 2014, he was appointed as the 7th Chancellor of the University of Birmingham and was the first Indian born Chancellor of a Russell Group University in Great Britain. Karan is Senior Non-Executive Director of the Booker Group PLC, the FTSE 250 Company of Booker Prize fame; he is one of the first two visiting entrepreneurs at the University of Cambridge; he is a founding member of the Prime Minister of India’s Global Advisory Council.

In 2006, Karan Bilimoria was appointed the Lord Bilimoria of Chelsea, making him the first ever Zoroastrian Parsi to sit in the House of Lords. In 2008 he was awarded the Pravasi Bhartiya Samman by the President of India. He is an honorary fellow of Sidney Sussex College Cambridge and Chairman of the Advisory Board of the Judge Business School, Cambridge University.

He qualified as a Chartered Accountant with Ernst & Young and graduated in law from the University of Cambridge. He is also an alumnus of the Cranfield School of Management, the London Business School and the Harvard Business School. In 2015, Karan Bilimoria was appointed President of the UK Council for International Student Affairs (UKCISA).

Linkin Twitter e-mail Website

Bio

An insightful legal, finance and diversity expert, Miranda Brawn has made a successful portfolio career for herself. Brawn has a robust track record managing teams and clients for the world’s largest banks, such as Goldman Sachs, JP Morgan Chase and Deutsche Bank. She has previously worked in senior middle office management roles and the front office as a sales trader. Today, Miranda manages the legal risk in Europe for derivatives, regulations and securities financing within an investment bank.Brawn has many strings to her bow and is well known for her passion in philanthropic and diversity issues. Moderator and public speaker for diversity, legal and finance events internationally. She advises ‘Game Changer’ firms and is their Ambassador in the media. Examples include where she is the Patron for the “Black British Academics” and the Vice-Chair for the “Black Cultural Archives”.She holds Post Graduate Diplomas in Management and Law, Master in Business Administration (MBA) degree in Strategic Management and Finance, passed the Bar of England & Wales (Lincoln’s Inn), studied News Journalism at The London School of Journalism & Political Philosophy at Cambridge University.

Linkin Website

Bio

Vipul Jain is a serial entrepreneur who specialises in spotting business opportunities while they are still in nuance stage. An MBA from Rochester Institute of Technology, Rochester, New York, class of 1999, I started my career by establishing a fabrics import business as an extension of the family business of Garment exports in 1999.

In 2002 I established an animation studio by the name of Mirage Animation which produces television quality animations for clients such as Warner Brothers, Disney, Channel 5 etc.

In 2003, I spotted an opportunity in Medical Tourism sector while the world was still to wake up to the phenomenon. Vipul helped founding a company called PlanetHospital and built it to be the worlds largest medical tourism company. I exited the company in 2011 to establish my own Medical Tourism business by the name of Mirage Medserv focusing on the third world countries, Russia, Africa and Mid East. Mirage is today one of the largest facilitators of patients of almost all major hospitals in the country.

In 2013, I established Advancells, which is a research based company focusing on providing cutting edge Stem Cell Therapies for patients with life threatening diseases also catering to lifestyle diseases and anti aging technology. Advancells is slowly rising to be a leader in a very small space of modern medicine and is in process of filing patents for treatment of multiple diseases.

Twitter Website

Bio

Navtej Sarna is a diplomat and author. He graduated from Delhi University in 1980 with degrees in Law and Commerce and joined the Indian Foreign Service the same year. He has served in various diplomatic capacities in Moscow, Poland, Bhutan, Geneva, Iran and Washington . His recent appointments were as the Foreign Office Spokesman and India’s Ambassador to Israel. Presently he is serving as a Secretary to Government of India in the Ministry of External Affairs.

Navtej Sarna is the author of the novels ‘We Weren’t Lovers Like That’ (Penguin India, 2003) and ‘The Exile’ (Penguin India, 2008) as well as the short story collection ‘Winter Evenings’ (Rainlight Rupa, 2012). His non-fiction works are ‘The Book of Nanak’ (Penguin India, 2003), ‘Folktales of Poland’ (Sterling 1991) and ‘Indians at Herod’s Gate’ (Rainlight Rupa, 2014). He has translated Guru Gobind Singh’s ‘Zafarnama’ (Penguin India 2011) from Persian to English as well as the Punjabi partition stories of Mohinder Singh Sarna in ‘Savage Harvest’ (Rupa, 2013). He has been contributing regularly to journals and newspapers in India and abroad including The Times Literary Supplement, London Magazine, The Hindu, India Today, Outlook and so on. His literary column Second Thoughts that appeared in The Hindu for seven years is being brought out as a collection by Harper Collins.

Linkin Website

Bio

Priya Krishnan is an MBA from London Business School and has worked in Various leadership positions with Anderson Consulting and Mphasis across Singapore, New York, London and India.Founder CEO of Founding Years Learning Solutions Pvt Ltd., India’s leading childrcare and schooling service provider with over 45 owned operated centres across Bangalore, Hyderabad, Mumbai, NCR and Chennai

She started the company with the intent of enabling women to get back to work post childbirth. With this in mind we provide high quality child care services onsite (for corporate like Unilever, ITC, L’Oreal, Johnson and Johnson, Airtel among others). We also work with corporates in near workplace models and help them with creating solutions for the employees through subsidies and underwriting (like in the case of Accenture, IBM, Flipkart etc.)

With 5 years of operations behind us and 2000+ children under our care what differentiates us is our transparency, flat organizational structure and empowered center staff.

She has worked across the world prior to moving to India to start up Klay and that experience has stood me in good stead.

e-mail Website

Bio

Phil Jackson previously held a range of senior positions within the Canadian healthcare system, as Director of Strategic Support and chief adviser to the Medical Officer of Health for the City of Toronto Health Department, the largest public health department in North America with 15 offices and 1,800 staff. Prior to this Phil led the development and establishment of the Ontario Agency for Health Protection and Promotion, with 14 laboratories and 600 plus staff, serving as the founding Vice President of Strategy and Planning. Phil served as part of the control team for the SARS outbreak in 2003 and the H1N1 outbreak of 2009.

Phil Jackson,As Head of Research to the Expert Panel on SARS, Phil led the drafting of a major two volume expert report into Infectious Disease Control and Emergency Response (the Walker report). Phil had served as the Canadian representative to the OECD working group on New Genetic Technologies and serving as Ontario Director for Health Information and Sciences led the drafting of an internationally acclaimed report on Genetic Testing. Phil has led a wide range of major health system initiatives in his career including leading the complete red-design of Stroke prevention, treatment and rehabilitation services for a population of over 11m people, the implementation of Hospital Report Cards across 134 hospitals, the establishment of 14 Regional Infection Control Networks and multiple other initiatives. Phil is the recipient of several Canadian awards for health reform, most recently the Amethyst Award and Ace Award.

Linkin e-mail Website

Bio

Dr. Anil Wali is currently the MD at Foundation for Innovation and Technology Transfer (FITT) – an autonomous industry interface organization of IIT Delhi. He is managing technologies and driving innovations and enterprise at the academia besides looking at issues of concern to SMEs. He has worked in chemical industry for 19 years before taking up the present position. Besides several publications, patents and reports to his credit, he has a strategic customer and quality orientation, and brings a practical perspective to solving technical problems. He is also called upon to deliberate and participate in the area of clean technology and sustainability. His multifaceted experience towards technology innovation and management, industry partnership, project issues, entrepreneurship, IPR, education, training, etc is sought for advice / association with several committees and programmes. He is an IIT Delhi Doctorate.

Dr. Anil Wali at Foundation for Innovation and Technology Transfer (FITT) believes that FIIT is an industrial interface organization, established at the Indian Institute of Technology Delhi (IIT Delhi) as a Registered Society on 9th July 1992. Dr NC Nigam was the founding Chairman of FITT, and Dr AK Sengupta was the first full-time Managing Director. IIT Delhi’s Review Committee Report -1986, recommended the setting up of an industrial foundation to enhance the programmes of interaction and collaboration between IIT and industry. To implement this recommendation the Institute took up this initiative, with a seed grant received from government at that time, which, led to the setting up of FITT.

FITT aims to be an effective Interface with the Industry to foster, promote and sustain commercialization of Science and Technology in the Institute for mutual benefits. For over twenty years now, FITT has been an interface between the Institute and the industry and has been devising innovative ways to create partnerships and linkages with business and community to enable knowledge transfer for common good. The team at FITT and academicians from IIT Delhi has been largely responsible for the successful outreach efforts including extensive S&T collaborations.

Linkin Twitter e-mail Website

Bio

Currently Julie Stone has responsibility for the leadership of Online Distance Learning at the University of Derby,and leads a team of staff dedicated to this business activity.

She was also involved, as Business Manager at University of Derby, in establishing the largest franchise within the HE sector and has led the Online Distance Learning project through to substantial and progressive growth.

As Head of Quality Assurance at Gloucestershire University, she helped the College of Higher Education achieve University status and gain degree of awarding powers.

Linkin Website

Bio

Dr Michel Baijot is Head of Cipla Global Vaccines. He is a life science executive bringing over 25 years of experience in building vaccine businesses with significant contribution in strategy, licensing, M&A, technology transfer and finance. His positions with both biotechs and big pharmas (GSK Vaccines, JnJ Crucell) and his concrete achievements in the vaccine marketplace reflect an in-depth knowledge of the vaccine environment in developed and developing countries. In his role of Head of Cipla Global Vaccines, he is leading the Cipla – Serum Institute of India partnership. He has been Chairman of the Belgian Biotech Association.

General/Business Unit Management, Healthcare, Big Pharma and Biotech,In Both Developing and DevelopedCountries,25 Years Worldwide Experience/Network in Vaccines, Mabs and Diagnostics

Linkin Website

Bio

Yvonne Naughton was previously Head of Business Development and New Product Planning in the UK and Ireland for over three years, and before that held several positions at Sanofi in market access opportunities in Paria and Ireland for cardio thrombosis and arrhythmias. Before Sanofi, she was clinical safety officer at Novartis, and worked in drug safety at Quintiles. She has a PhD in Pharmacology from University College Dublin.

Yvonne Naughton was leading the UK and Irish side of our Global External Science & Partnering organisation. Our remit is to collaborate externally with academic institutions, spin-outs, start-ups, biotechs and non for profit organisations, in order to build Sanofi R&D’s early stage pipeline and accelerate the translation of innovation discovered in the UK and Ireland.

A strategic priority for Sanofi is to sustain innovation in R&D. We will increase our annual global R&D investments to €6bn by 2020, with an increased capacity for external innovation.
Our research interests and investment focus fall into 2 categories. 1: Where we would like to sustain our leadership- Diabetes, Cardiovascular Disease and Genetic Rare Diseases. 2: Where we would like to build a competitive position- Immunology, Oncology and Multiple Sclerosis. We will also invest opportunistically in Neurodegeneration/Pain, Infectious Disease and Ophthalmology.

Linkin Website

Bio

Yichen Shi gained his doctorate in neuroscience and stem cell biology from the University of Cambridge. During his research he identified the need for a high-quality supplier of human cells; both iPSC-derived and primary, complete with media, supplements and all the critical ingredients for successful research with human cells. His entrepreneurial spirit combined with his passion for cell-biology led to the creation of Axol where innovation, quality and customer service are the key drivers.

Axol produces highly validated, human cells and critical reagents such as media and growth supplements. We have a passion for great science, delivering epic support and innovating future products to help our customers advance faster in their research.

Our expertise includes reprogramming cells to iPSCs and then differentiating to various cell types. We supply differentiated cells derived from healthy donors and patients of specific disease backgrounds. As a service, we also take cells provided by customers (primary or iPSC) and then do the programming (when necessary) and differentiation.

Linkin Twitter Website

Bio

Venkateswarlu Nelabhotla comes with a very rich and global experience of successfully leading organizations in the Life sciences and Consumer Products businesses. He has held top management roles in the life sciences space in companies like Shantha Biotech (A Sanofi Company) and Aurobindo Pharma and he immensely contributed to their all-round growth. Shantha Biotech – a biosimilar and vaccine company, was eventually acquired by Sanofi for around $ 800 MN in 2010. He has been a part of significant revenue growth and significant value creation in Aurobindo Pharma in the global business segment of APIs and finished dosage form products in multiple therapy areas. He has held CEO roles in Emami and Cavinkare, CPG companies, growing them significantly with an all rounded approach. During his stint at Emami (a listed company) as CEO, the company’s market cap went up from $ 300 MN to $ 1.2 BN. The momentum thus created, has made Emami a $ 3.7 BN market cap company now. During early part of his career, he created some very successful brands in Cavinkare, a leading CPG company from India, and built the organization with a 10X revenue increase in 6 years’ time and that early momentum has made Cavinkare one of the established Consumer product companies in India. He comes with core strengths in Strategy, Innovation, Marketing, Organization building, Finance, M&A and Governance. He has been an integral part of many industrial forums in Life sciences and CPG business.

Website

Bio

Stephen Shuttleworth joined Karus as CSO in 2008, and is the founding scientist of the company’s PI3K-p110β/δ and HDAC6 programs. Over the last 21 years, he has established a strong track record in R&D management, and in the design and development of molecular-targeted therapeutics for cancer, immune-inflammation and metabolic diseases. Prior to Karus, Stephen held senior positions in UK and North American biotech, notably at Celltech-Chiroscience (UK), BiochemPharma-Shire (Quebec), Tularik-Amgen (California), CRUK, and Piramed (UK) where he directed the PI3K-p110α and p110δ programs, designing and leading the preclinical development of GDC-0941 (Pictilisib), currently in Phase II cancer trials, under the auspices of Roche, who acquired Piramed in 2008 for $175M.

Stephen Shuttleworth has authored over 130 publications and patents, has been an invited speaker at over 40 major international conferences, and is a recognized opinion leader in the PI3K and HDAC arenas. He obtained his BSc and PhD in Chemistry from the University of Liverpool, and was made a Fellow of the Royal Society of Chemistry in 2007.

In 2014, he was appointed Professor and Honorary Chair at the University of Manchester (Faculty of Medical and Human Sciences) in recognition of his work on small molecule drugs to treat chronic human diseases.

Linkin Website

Bio

Dr. S.D. Ravetkar is an Executive Director with Serum Institute of India Ltd. Apart from his Doctorate he holds degrees in Management and Finance. He has authored various research articles in national and international journals. He is also on advisory board of various national and international organizations and journals. He has more than 43 years techno-commercial experience in biotech industry in various areas like QC, production, projects planning & research. At present his major responsibility is manufacturing of Bacterial combination vaccines mainly Pentavalent and Hexavalent vaccine. He has extensively worked on microbial and bioengineering aspects of vaccinology and also has got expertise on technology transfer. He has widely traveled worldwide. He is listed amongst 15 influential figures in the Asian Vaccine Industry.

Dr S D Ravetkar, Executive Director, Serum Institute of India says that the company has put programme in place to achieve the ambitious plan to offer new vaccines

Serum Institute of India Ltd., is the worlds no. 1 producer of Diphtheria, Tetanus, Pertussis, HIB, BCG, Hepatitis B, Measles, Mumps, Rubella vaccines. It is estimated that about 60% of the children in the world receive at least one vaccine manufactured by Serum Institute of India Ltd.

Key focus in the coming year will be enhancing further capacities of above vaccines for which state of art plants are under various stages of completion. The growth has its own problems and challenges. Planned programme has been put in place for handling these issues.

Major thrust is also given on further strengthening quality systems by adding Process Analytical Technology (PAT) in various stages of manufacture of vaccines. More focus is given on incremental innovation than only on disruptive innovation. The technical team building by establishment of new training center is given major thrust.

Serum is also working with various Universities and Research Institutions in country and overseas, in Europe and U.S. to leverage advantage of mutual strengths in knowledge building. The development of critical knowledge mass is thus at center of various activities.

With robust pipeline of various newer vaccines in offing structured programme is carried to reduce time to market. Products on the horizon are many like Rota and Pnemococcus and HPV vaccines. This in itself is a gigantic task of putting new R & D incubators and going through entire process of germination of idea till commercialization.

Innovation is also being implemented in supplying various new vaccine administration systems and for effective measurement thereby validation of cold chain management.

These efforts will help make vaccines available at affordable cost to infant population in world. With acquisition of Bilthoven Biologicals in Netherlands Serum Institute of India Ltd., is looking for entry in Western regulated markets, In years to come as our vaccines are already manufactured in world class environment confirming to International FDA.

Linkin Website

Bio

Sakate Khaitan is the senior partner at Khaitan Legal Associates. Sakate divides his time between London and Mumbai.

Sakate Khaitan heads the corporate M&A, funds, restructuring and insurance practice at Khaitan Legal Associates. Sakate advises clients on inward investments into India and on an array of India-focused cross border transactions. Having started his career in litigation, Sakate has over 11 years of litigation experience advising various clients in their disputes that included high profile joint venture disputes, tax disputes and disputes with regulators. Sakate also serves on the boards of several companies as a non-executive director, lending his legal and business acumen to businesses around the globe. Sakate assists clients with pragmatic and commercially sound advice on dealing with Indian rules and regulations. His clients include multinationals, private equity funds, financial institutions, fund managers, and HNIs.

In his experience that spans over two decades Sakate Khaitan demonstrates a deep commercial understanding of several industry sectors and significant transactional insights that offer immense value to the client.

Sakate Khaitan is the alumnus of London Business School (“LBS”) and is also the co-founder of the India Business Forum (“IBF”) at LBS. The IBF is a platform that was created to build awareness and facilitate discussions on and encourage cross border investments to/from India.

Sakate Khaitan is dual qualified and is a member of the Bar Council of India and is also admitted as a solicitor of the Supreme Court of England and Wales. However, he exclusively practices Indian law.

Linkin Website

Bio

Dr Maryam Atakhorrami is an Industrial Partnership Manager with Translational Research Office in UCL. She works with key stakeholders of Faculty of Medical Sciences, to identify, create and manage strategic industrial partnerships for selected priorities of UCL in medical sciences. Maryam has a PhD in Biophysics from Vrije Universitiet Amsterdam. She has extensive experience of working in health care industry in various corporate Research and Innovation function, predominantly with a focus on new business development, strategic research alliances and open innovation management in private and public sector.

The Faculty of Life Sciences undertakes world-leading research and teaching, which combines the strengths of UCL’s basic biological and preclinical sciences. Our work attracts staff and students from around the world and together they create an outstanding and vibrant environment for both students and researchers. It is one of four Faculties within the UCL School of Life and Medical Sciences.

Research in Biosciences is carried out in Research Departments which bring together a critical mass of individuals with related interests. The Research Departments span the scale required to understand biological systems from molecules through to populations.

Linkin Website

Bio

Rahul Garella is Senior Vice President, Head of International Pharmaceuticals at Endo Pharmaceuticals

– Leadership experience with full P&L responsibility for European subsidiaries.

– Top line and EBIDTA targets and overall P&L management and delivery.

– Leadership and strategy to bring differentiated generics and speciality products across Western Europe.

– Business strategy including licensing, building front ends, acquisitions and partnering

– Rich geographical experience in Europe, Asia Pacific and South America

– On the Editorial board of ‘Journal of Generic Medicines’ Past Recognitions/Awards:

– Led Glenmark, UK and achieved recognition for business performance by the London Stock Exchange group through their publication ‘1000 Companies to Inspire Britain’ (www.1000companies.com) in December’13

– Achieved recognition for Glenmark as amongst the fastest growing companies in the UK though a report by the CII (Confederation of Indian Industry) and Grant Thornton in its report ‘India meets Britain’ in March’14‘ Specialties: Business development for Generics (APIs and finished dosages) with companies in Europe, Latin America and Asia Pacific.

Recognition/Awards:

– Led Glenmark, UK and achieved recognition for business performance by the London Stock Exchange group through their publication ‘1000 Companies to Inspire Britain’ (www.1000companies.com) in December’13

– Achieved recognition for Glenmark as among the fastest growing companies in the UK by the CII-Grant Thornton in their report ‘India meets Britain’ in March’14‘

Linkin Website

Bio

Naveraj Gill joined the department in 2002 to complete an EngD in collaboration with HEL Ltd. The project was based on the design and characterisation of an automated miniature bioreactor system for microbial culture. Following this Nav remained in the academic field as a postdoctoral researcher at UCL. She first worked on a large Technology Strategy Board (TSB) grant in collaboration with the Health Protection Agency (HPA) and Syntaxin.

Naveraj Gill research focused on the integration of microscale technology for the rapid development of bioprocesses and design for manufacture of biotherapeutic fusion proteins. She then worked as part of the IMRC in Bioprocessing investigating ultra scale-down microwell-based techniques for studying mammalian cell culture processes for the production of biopharmaceuticals with a view to scale-up to conventional and single-use bioreactor formats. This led to a position with GE Healthcare as a Single-Use Technologies Specialist, which evolved into a wider business development role for upstream technologies covering UK and Ireland. Key responsibilities included designing in single-use technologies, devising strategies for growing the upstream business, consulting on new product developments and managing new product launches.

Naveraj Gill has now returned to UCL as the Strategic Alliance Director to support the department in forging new links with companies and to foster existing relationships, creating a platform for knowledge transfer. She manages the MBI® industrial training programme which has trained over 1,300 individuals from 300 international companies and is the Business lead for the VISION Programme for Senior Executives.

Linkin Website

Bio

Keith Foster, VP of Ipsen bought the biotech and its drug development platform Syntaxin for $37 million upfront with promises of about $170 million more, with most of the money pinned to the fate of a mid-stage therapy for a rare ailment. Dr Foster is a co-founder of Syntaxin, and joined Ipsen to build a botulinum toxin biology platform for new drug development covering a variety of fields. Back in 2010 Ipsen joined a consortium of investors to put $29 million into Syntaxin. The company held a 10% stake in Syntaxin at the time of the buyout.

Linkin Website

Bio

Kay Brickmann is an experienced PhD business development and licensing professional with a significant track record of successful negotiations and completed deals. More than 17 years of post-doctoral experience in the pharmaceutical industry with scientific expertise in the field of cardiovascular R&D evidenced by author-/co-authorship of 15 research papers and 13 patents. Transactional experience with entities in Europe, USA, Japan and China, full understanding of the pharmaceutical drug development process from early discovery to marketing and a fluent German, English and Swedish speaker.

Recently, Kay Brickmann reported ethyl nicotinates as antagonists of the P2Y12 receptor, which is an important target in antiplatelet therapies. A potential liability of these compounds was their generally high in vivo clearance due to ethyl ester hydrolysis. Results: Shape and electrostatic similarity matching was used to select five-membered heterocycles to replace the ethyl ester functionality. The 5-methyl and 5-ethyl-oxazole bioisosteres retained the sub-micromolar potency levels of the parent ethyl esters. Many oxazoles showed a higher CYP450 dependent microsomal metabolism than the corresponding ethyl esters. Structure activity relationship investigations supported by ab initio calculations suggested that a correctly positioned alkyl substituent and a strong hydrogen bond acceptor were necessary structural motifs for binding. In rat pharmacokinetics, the low clearance was retained upon replacement of an ethyl ester with a 5-ethyl-oxazole. Conclusion: The use of shape and electrostatic similarity led to the successful replacement of a metabolically labile ethyl ester functionality with 5-alkyl-oxazole bioisosteres.

Linkin Twitter e-mail Website

Bio

Denise is a NewLaw pioneer and has been spearheading operational, structural and cultural change within the legal services industry since starting Halebury in 2007. Her aim: to create an entirely original business model to service the needs of clients and lawyers at the senior end of the market. Denise has persuaded many clients, who would generally look to a panel of large firms for legal advice, to try a new service delivery method. The firm now has strategic partnerships with clients such at BT and Expedia, a growing roster of clients in the TMT and FS sectors and a team of 30 senior in-house lawyers. Denise is client lead on many of these accounts and heads up both service and product innovation to continuously improve and develop Halebury’s proposition.

Denise is a gamechanger in more ways than one. She has successfully and uniquely combined her legal and television career, launching and managing Halebury whilst presenting for Sky News and BBC One’s Escape to the Country. She continues with her media career as she strongly believes that experiences outside the legal industry can enhance your legal outlook and lead to innovation. She combines both careers with raising a young family.

Denise’s vision and determination to create an alternative in the traditional legal services market is borne out by Halebury’s success, evolving business model, recognition in the marketplace, and growing roster of high quality clients. She remains passionate about collaborating with clients to anticipate and meet their requirements. Her lead on customer service within the business has led to her being asked to speak on the subject to FTSE 100 clients.

Linkin Website

Bio

Kartik Kumaramangalam has worked with multiple high tech startups in his career as an investor and early stage co-founder including Webex (acquired by Cisco) where he was an early founding employee. He has worked in private equity consulting at Boston Consulting Group in New York, and has been a hands on venture capital investor in several successful early stage technology companies in the US and India. Kartik’s undergraduate and master’s degrees are in Astrophysics undertaking research in solar neutrinos at Oxford University, before switching fields and completing his PhD at the London School of Economics as an Interdisciplinary Scholar for his applied mathematical research on scientific labor markets. He is currently also a Visiting Fellow at MIT.

Kartik Kumaramangalam is an active investor and advisor to start-ups and investment projects in Singapore, India and the US. He has previously worked at Boston Consulting Group in New York, been an early employee at WebEx (acquired by Cisco), advised the organization of His Holiness the Dalai Lama on economic policy and was a researcher on a Nobel Prize winning experiment in Astrophysics at Oxford University.

Kartik Kumaramangalam is also a Fellow at MIT and has taught and done research at MIT, London School of Economics and London Business School on the economics of intellectual property and tech driven economic growth. Kartik completed his PhD at the London School of Economics as an Interdisciplinary Scholar winning the Academy of Management Award for his research on scientific labor markets and the economics of ideas. He first trained as an an Astrophysicist specializing in solar neutrino physics as an undergraduate and graduate student at the University of Sussex and the University of Paris.

Kartik’s commitment to economic development comes from a strong background in public service in India with family members who have served as the Governor of Maharashtra, Chief Minister of Madras Presidency, Chief of the Indian Army, Cofounder of Air India (the national carrier) and Cabinet Ministers for Law, Education, Company Affairs, Power, Science, Technology, Coal and Mines.

.

Linkin Website

Bio

Karin Conde-Knape is Vice President of Cardiovascular & Metabolic Scientific Innovation at Johnson & Johnson Innovation, London.

Previously, Karin was Global Head of Discovery in the CVM DTA at Roche where she was responsible for all the Early Research efforts as well as the Translational Biomarker and experimental medicine group. While at Roche, Karin was directly or indirectly responsible for identifying and managing numerous external collaborations with well renowned institutions worldwide. In addition, throughout her career at Roche, she had several roles, including laboratory head, project leader, head of pharmacology and co-department head in the CV and Metabolism Disease and Translational Area, both in the US and in Switzerland. She was responsible for setting and implementing the pharmacology strategy for the portfolio in the CVM group in areas such as Diabetes, Atherosclerosis, Dyslipidemia, Kidney, and CV disease.

Karin received her PhD in Nutritional Sciences from the University of Connecticut, and completed her post-doctoral fellowship at Columbia University.

Responsible for identifying, establishing and managing External Scientific opportunities from Early research to Clinical POC in the aread of Cardiovascular and Metabolism.

Linkin e-mail Website

Bio

Gaurav Mehra joined Kaizen in 2015 and leads the fund’s Education Technology investments. Prior to joining Kaizen, he co-founded Saba and helped build it into a $150 million public company and a global leader in Talent Management software solutions. With 25 years in building technology and scaling global product and service operations, Gaurav helps portfolio companies shape defensible growth strategies. Gaurav holds BS and MS degrees in Computer Science from Stanford University. As a Partner with Kaizen, an Education, EdTech and HCM focused fund, I evaluate deals, and work with our portfolio partners on operational and scaling challenges.

Linkin Website

Bio

Jonathan  Tobin joined Imperial Innovations in 2011 and specialises in therapeutics and diagnostics investments. He is a board director with antibacterial drug discovery company Auspherix, and diagnostics companies Abingdon Health and Molecular Vision, and a board observer with Cell Medica and Psioxus. Prior to joining Imperial Innovations he worked at MRC Technology, sourcing and evaluating new opportunities for small molecule and antibody drug discovery worldwide. He has a PhD in molecular medicine from UCL, and undertook post-doctoral research at the Cancer Research UK LRI. Jonathan has a First Class degree in Biology from Oxford University and an MBA with Distinction from Imperial College.

Jonathan  Tobin is a life science specialist with experience of early and later stage venture capital deals, specialised in therapeutics and diagnostics. Board director of two specialist diagnostics companies and one drug discovery company, board observer of two biotechs and one molecular diagnostics company.

Drug discovery and business development experience; strong science background (PhD, post-doc, ten publications plus book, and numerous scientific awards and scholarships; MBA with Distinction from Imperial College; First Class degree in Biology from Oxford University.

Jonathan Tobin is a non executive director at artios and Artios is developing inhibitors of DNA Damage Repair enzymes to selectively kill cancer cells through a concept known as ‘synthetic lethality’. This has been demonstrated with the recent success of PARP inhibitors in clinical studies, and the launch of Lynparza™ (olaparib; AstraZeneca). DDR targeted products have the potential to be used in combination with other cancer agents to help prevent cancers from reoccuring.

Artios has in-licensed its lead DDR programme, PolƟ, from Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK) and continues to work with CRT and other experts in the field to build its pipeline of novel DDR programmes.

In September 2016, Artios raised a £25m Series A from a syndicate including SV Life Sciences, Arix Bioscience, Imperial Innovations, Merck Ventures, Abbvie Ventures, and Sixth Element Capital.

Linkin Website

Bio

Dr. Kaushik D. Deb, a Heath Care Biotechnology Professional working on developing solutions to unmet medical needs and personalized precision therapies. Developed technology platforms for commercialization and out licensing. Also interested in Rural health care and Clinics. DiponEd is a P4M company (preventive, predictive, participatory and personalized medicine). Merisis Therapeutics – is a fully owned SBU of DiponEd and is involved in the (R&D) development and commercialization of US FDA etc compliant cell processing units, modular clean rooms, BMT / HSCT units, Celluar Therapeutics, Immunotherapies in cancer/ pain/ allergy/ autoimmunity etc, Biologicals, Biosimilars and 3rd Generation Implantable devises and Biomaterials. Also researches in nanobiotechnology, directed stem cell trafficking technologies and integrating Regenerative and Complementary medicine. We work as technology service providers to Corporate Hospitals, Not for profit organizations and Clinics treating Unmet and No-Option medical Conditions.

Dr. Kaushik D. Deb is the founder and director of DiponEd and DiponEd is a P4M company (preventive, predictive, participatory and personalized medicine).

Merisis Therapeutics – is a fully owned SBU of DiponEd and is involved in the (R&D) development and commercialization of US FDA etc compliant cell processing units, modular clean rooms, BMT / HSCT units, Celluar Therapeutics, Immunotherapies in cancer/ pain/ allergy/ autoimmunity etc, Biologicals, Biosimilars and 3rd Generation Implantable devises and Biomaterials. Also researches in nanobiotechnology, directed stem cell trafficking technologies and integrating Regenerative and Complementary medicine. We work as technology service providers to Corporate Hospitals, Not for profit organizations and Clinics treating Unmet and No-Option medical Conditions.

The other activities of DiponEd are related to development of personalized solutions in cell based cosmetics, antiaging, wellness, sports medicine and advanced nanotechnology based FMCG and OTC personal health care products.

Linkin Website

Bio

David Horn Solomon has strong operational and innovation-minded Healthcare Investor, CEO, Board Member, leader, strategic thinker, and decision maker with success- and problem-solving orientation and the ability to assemble strongly motivated high-performance teams. 30 years of experience in the life sciences—biotechnology—pharmaceutical—investing industry in a range of high-level executive positions in various countries.

David Horn Solomon, President and CEO of Bionor Pharma ASA since January 2015, a publically listed healthcare company based in Oslo, Norway, with offices in Copenhagen, Denmark, and New York, NY. From 2008 to 2015 I served as President and CEO of Zealand Pharma A/S, a NASDAQ OMX Company. Before joining Zealand, I held leadership positions at several biotechnology, pharmaceutical and medical device companies. I have extensive experience in pharmacology research, having served as a faculty member at Columbia University’s College of Physicians and Surgeons in New York, NY.

Linkin Website

Bio

Pharma:
Imran Kausar is a Medical doctor and professional in pharmaceutical medicine (big pharma/biotech). Worked on brands as diverse as Viagra to Esbriet (orphan designated for IPF). Worked in start-ups till acquisition (InterMune).

Halal Food/Islamic Markets:
Founded Halal Food Festival in London, 2013. A 3 day consumer food show aiming to showcase the expanding halal markets [www.halalfoodfestival.com]. Co-Founded Haloodies, a premium halal meat brand in the UK. On sale via Ocado. Numerous media interviews on BBC, CNBC, The Financial Times, The Economist, The Guardian

Speaker:
World Islamic Economic Forum Cordoba Roundtable, March 2015
World Islamic Economic Forum, 9th Forum, London, 2013

Investor:
Interested in early stage funding of companies with a social entrepreneurial interest.

KKR Halal Ltd operates Haloodies (Halal Foodies) the halal food brand aimed at a new generation of halal consumers. Haloodies aims to be the first, global halal food brand by providing high quality halal products aimed at Muslim millennials.

Please find out more information at www.Haloodies.com

Imran Kausar was responsible for creating a medical department in a newly formed local affiliate of a US biotech. Responsible for creating a medical team, SOP’s, quality, education, MHRA inspections, regulatory, public affairs, KOL management, PV.

Imran Kausar had held various positions at Pfizer whose responsibilities included: Responsible for EU medical strategy for pulmonary vascular medicine including business development, label enhancement and safety management for sildenafil in pulmonary arterial hypertension.

European Pulmonary Vascular Diseases Unit.

Pulmonary Vascular Business Unit
First Line Manager
Country and European Team responsibility

Linkin Website

Bio

Dr Shawn Manning is a Managing Director with Outcome Capital and manages its European operations in London. Outcome Capital is an independent investment banking firm committed to enhancing the corporate and shareholder value of innovative life science companies. Prior to joining Outcome Capital Manning founded Akesios Associates, a specialist advisory firm providing financial strategy, representation and commercial development advice to Life Science companies, with a current focus on IPOs, M&A and portfolio strategy. He has a keen interest in strategy, modelling and outcome optimisation, with a particular focus on oncology, neurology, antibodies, vaccines and the potential strategies impacting the transmission of infectious disease.

Dr Shawn Manning has over 25 years of international Life Sciences experience, including over 12 years as a rated equity analyst (with Dresdner Kleinwort Benson, SG-Cowen/ Société Generale, Bridgewell/ Landsbanki and Singer Capital Markets), covering ‘Big Pharma’, speciality/emerging pharmaceutical, and biotechnology stocks. Over 2006-2012 he helped develop one of the City of London’s leading Life Science Corporate Advisory franchises, his research and advice supporting the raising of over £400m in new funding for Life Science companies. Before entering the City, Manning spent 5 years consulting to the pharmaceutical industry, and managing Datamonitor’s Healthcare practice. In this capacity he worked alongside major European, US and Japanese pharmaceutical companies, leading consultancy projects focusing primarily on strategic product positioning, including portfolio, opportunity and pricing analysis. Manning originally specialised in infectious disease, and holds a Doctorate from the University of Oxford (Hertford College), and a BSc (Hons) and ARCS from Imperial College, London. He is a Fellow of the Royal Society of Medicine, a member of OBN’s Advisory Board and Chairman of OBN’s investment Special Interest Group (iSIG).

Manning is Managing Director at Outcome Capital LLP is a multifaceted technology and life sciences investment banking firm that provides middle-market growth companies with an innovative client-specific approach to private equity and merger and acquisition advisory services. We are passionate about innovation with a mission to facilitate significant positive impact on our companies. We are interested in companies that possess a portfolio of transformative assets, a bold vision and a desire to achieve excellence. We take pride in our ability to enhance value and assist our clients with aligning business objectives with strategic opportunities and transactional expertise.

Linkin Website

Bio

Carl Sterritt, with approximately 20 years’ of management and executive level experience in pharmaceutical development and commercialisation in both large and small company settings, Carl has led the Company as its CEO since he co-founded the Group in 2008 together with Dr.Christian Schweiger.

Carl Sterritt held senior management roles at United Therapeutics and Encysive Pharmaceuticals, working on innovative therapies for the treatment of pulmonary arterial hypertension. Carl joined United Therapeutics to establish the company’s European operations in preparation for the marketing approval of Remodulin®, running the subsidiary for six years. In collaboration with physicians in Germany, he was responsible for and holds patents related to United Therapeutics’ decision to develop and commercialise treprostinil; now successfully commercialised in the US as Tyvaso™. Carl was instrumental in the successful commercial launch of Thelin™ and the rapid growth of Encysive’s European operations. Carl founded the Group after Encysive was acquired by Pfizer Inc. for more than $300m.

Since founding Shield Therapeutics plc – a successful and growing specialty pharmaceutical company commercialising novel prescription therapies – Carl has raised close to £70m and led the team that has successfully developed Shield’s two leading assets, Feraccru® and PT20, recently resulting in the approval of Feraccru and completion of Shield’s IPO on the LSE. During this time Shield has also taken PT20 – a treatment for hyperphosphataemia – through a 1st pivotal study, leaving one study to be completed before a marketing authorisation application.

With an under/postgraduate background in life sciences and an MBA from Henley, Carl has approx. 20 years of experience in pharma. Trained in the large pharma environment, he quickly moved into orphan and specialty medicines, working for United Therapeutics as a core member of the Company’s commercialisation team that launched Remodulin® in the USA, after which he established and led the company’s European operations for 6 years. In collaboration with physicians in Germany, he was responsible for and holds patents related to the development and commercialisation of an inhaled form of treprostinil – now commercialised as Tyvaso™. This was followed by a period at Encysive Pharmaceuticals, leading European commercial operations and delivering the successful launch of Thelin™ another treatment for pulmonary arterial hypertension. The company was acquired by Pfizer for over $300m in 2008, following which Carl left, eventually establishing Shield Therapeutics.

A creative, lateral thinker with proven entrepreneurial flair and a clear record of delivering shareholder value. Key strengths include business leadership experience, creation and delivery of effective business strategy, as well as effective communication and relationship building capabilities.

Outside of work Carl enjoys spending time with his family, socialising and participating in or watching a variety of sports.

Linkin e-mail Website

Bio

As Director of Legal Services UK – Global Accounts (Complex Contracting), Rory O’Keeffe works on and help manage a team of transactional lawyers with a wide array of – external client facing – high value commercial matters affecting Accenture in United Kingdom and Ireland and, at times, within Europe, including: consulting, outsourcing, operations, strategy and digital.

His previous experience involved working in both in-house and private practice advising on all legal fields, especially construction, energy and commercial matters, including contracts, dispute resolution, client management (domestic and international) and training.

Linkin e-mail Website

Bio

Ross Woodham is Director of Legal Affairs and Privacy Officer at Cogeco Peer 1, based in the UK and part of Cogeco Communications, Inc. (TSX:CCA) who are headquartered Montreal, Canada.

Cogeco Peer 1 is a multi-national hosting company with data-centers located across the United States, Canada and the UK, with further points of presence in Europe. It provides collocation, managed and cloud hosting services to some of the world’s most respected and trusted household names.

Ross has been working with hosting providers, top-tier technology companies and their clients for over 8 years, first in private practice and then later joining Cogeco Peer 1 in 2012. He is responsible for the legal and business affairs of Cogeco Peer 1’s EMEA business and its global data privacy strategy.

Linkin e-mail Website

Bio

Sharon was then appointed as Chief Executive of The Scottish Institute for Enterprise, a partnership of all twenty of Scotland’s higher education institutions. She was a board member of the government driven Science Enterprise Centre’s and the National Council for Graduate Entrepreneurship. Sharon Sharon also served as a Trustee of the Glasgow School of Art for three terms.

In 2007 she became founding chief executive of the UK India Business Council (UKIBC), where she built the foundations of the organization; creating the brand, expanding its network, developing its outreach and engagement programs and building the organisations team in the UK and India.
Sharon is also Chairman of Chynoweth Technologies, a high tech investment company and is currently on the International Business Advisory Board for Waikato Management School, New Zealand.

Twitter e-mail Website

Bio

Prof. Madan Mohan Pant is an internationally renowned expert specialising in pedagogy, technology and the development of tools and curricula for 21st century education. He has been known for developing, working models that enhance the pedagogy using latest available technologies. He is especially noted for his efforts in leveraging social media for improving learning and bringing the mobile into the classroom where it has been traditionally banned.

Prof. Pant’s current work and interests revolve around the development, delivery and promotion of educational products, processes and services that cater for the needs and interests of future learners, a framework that is named “Learning 221”.

His past roles include being the Former Pro-Vice Chancellor, Indira Gandhi National OpenUniversity (IGNOU) and being on the faculty of IIT, Kanpur (the premier engineering institution in India), MLNR Engineering College and Faculty as well as Visiting Professor, University of Western Ontario, Canada.

He has been a visiting scientist at European research centres in Italy, England, Germany and Sweden. Prof. Pant is the founder of the LMP Education Trust, an organisation that promotes new age learning and supports under privileged learners.

Prof. Pant has been associated with many educational organizations as member of committees or working groups, such as the NCTE, NCERT, CBSE, NIOS, NUEPA, CEC, UGC, AICTE, AIMA and several Universities. He has been closely linked with the IIT system, having got his Ph.D from IIT, Roorkee, a faculty member at IIT, Kanpur and a member of the Board of Governors, IIT, Delhi.

Linkin Website

Bio

Linkin Website

Bio

Ajay Rajan Gupta works as a Consultant Orthopaedic Surgeon in the National Health Service with subspeciality interest in Knees and Hip arthroplasty

The INDO UK INSTITUTE OF HEALTH MEDICITIES PROGRAMME was announced as a Joint Statement between Prime Minister of UK Mr David Cameron and Prime Minister of India Mr Narendra Modi in London on 11th November 2015.

https://www.gov.uk/government/news/india-and-the-uk-establish-a-strategic-partnership-in-healthcare

The Programme is supported by-

. IUIH Company structure and Corporate governance was done by KPMG UK
. IUIH Programme Management for next 10 years – EY LLP London
. IUIH Procurement Strategy and Advisors- PwC London and Apira Consultancy
. IUIH Implementation Meetings every month at Healthcare UK (DIT/NHS/DOH)-
https://www.gov.uk/government/organisations/healthcare-uk

The programme celebrated its 1st year anniversary at the Indo UK Technology Summit in Delhi by Prime Minister of UK Theresa May and Prime Minister of India Mr Narendra Modi inaugurated by November 2016. Rt Hon’ble Dr Liam Fox Sec of State for Trade and Industry chaired a IUIH Roundtable to celebrate this event.

Linkin Google+ Website

Bio

Ajan Reginald is a hugely accomplished and widely recognised expert in the fields of Science and Medicine. Ajan Reginald co-founded Cell Therapy Ltd (CTL) in 2009 with Professor Sir Martin Evans, Nobel Laureate 2007 and CTL is an award winning biotech company developing stem cell therapeutics with clinical programs.

CTL (Cell Therapy Limited) develops cellular medicines to treat life threatening and life altering diseases and is currently focused on CVS indications: Heart Failure and Myocardial infarction. Prior to this Ajan Reginald was Global Head of Emerging Technologies at Roche Pharmaceuticals in which he led efforts to identify and commercialise the best breakthrough life science technologies including a focus on Stem cells. Before Emerging Technologies,

Ajan completed over 30 licensing and acquisition transactions a Business Development Director at Roche. From 2003-2005 Ajan worked with the Boston Consulting Group in the USA & Zurich as a member of both the Life Sciences Practice Area and Intellectual Property Group. Ajan is a Fulbright scholar, a graduate of London Hospital School of Medicine and Dentistry and holds an MBA from the Kellogg Business School at Northwestern University. Ajan enjoys spending time with his wife and young son and in his spare time he plays competitive Hockey, representing England at the over 40’s level.

Ajan Reginald
– Executive Director Cell Therapy Limited (CTL): CTL develops cellular medicines to combat life threatening and life altering diseases.
– Ex-Global Head of Emerging Technologies, Roche
– Ex-Business Development Director, Roche
– Consultant, Boston Consulting Group
– Kellogg School of Management
– Fulbright Scholar
– University of London

Linkin e-mail Website

Bio

Professor Heather Tarbert is a Professor of Financial Management at the University of the West of Scotland. She is the author of many journal papers, independently rated as of internationally excellent quality in the most recent UK Research Excellence Framework exercise.

Heather has previously worked at other internationally renowned UK universities such as Heriot-Watt and has taught on the triple accredited University of Strathclyde MBA in various international locations. She is also the co-author of the book “Corporate Finance for Business” published by Oxford University Press.

Heather is also an expert in the CIMA Financial Strategy syllabus and is a visiting professor at two Chinese Universities, one of which is one is UIBE, which is widely considered to be one of the leading Chinese Universities in economics, finance and international business.

Linkin e-mail Website

Bio

Michael’s role is to lead on the development of academic initiatives and update existing ones as we continue to expand our range of study programmes.

Michael was appointed to this role in February 2012, following a successful three-year appointment as Director of Education with the College of Estate Management, which operates in more than one hundred countries.

With more than twenty years experience in education, Michael started his career with KPMG, where he qualified as a Chartered Accountant. His experience in education includes fourteen years with Edinburgh-based, Heriot-Watt University. There he was responsible for designing, developing and managing a suite of international undergraduate degree programmes, all designed for distance learning, in finance, accountancy and business.

Michael was also employed by the ifs School of Finance, formerly known as the Chartered Institute of Bankers (CIB), where he played a key role in securing TDAP (Taught Degree Awarding Powers) for the school.

Michael, holder of a First Class MA in Accountancy and Finance, from the University of Dundee, is experienced in teaching. He has also contributed towards the work of a number of academic bodies, as well as being widely published within his field.

Linkin Website

Bio

Sumit Munjal is interested in opportunities that includes Contract

– UK- General Medical Council (GMC) registered physician with license to practice and NHS-England clinical experience in both acute and primary care settings.
– Masters in Epidemiology from London School and academia experience in Pharmaco-Epidemiology.
– UK MHRA and EMA Drug Regulatory Authority experience.
– Pharmaceutical industry experience in both rapid evolving Oncology medicine and more Established medicine products portfolio.
– Working in Global matrix teams for drug development and license.
– Line/team/Therapeutic Area management.
– PV Leadership and CRO oversight experience.
– Global Safety Lead experience
– PV regulatory documents review and sign-off.
– Audit/inspection experience
– Both contract and permanent work experience.
– Experience of speaking and invlovement at various reputed pharmaceutical/healthcare international conferences.
– Background of developing country/emerging markets experience.
– Understanding of healthcare, public health priorities and people management.

Sumit Munjal currently works as Takeda Global Safety Lead ~600 Marketed licensed products and his,
Responsibility of Risk management, aggregate safety, labelling and all PV maintenance activities
Management Therapeutic Area/ Team physicians and scientists /processes
Due dilligence activities
Appraiser for company physicians, Takeda Designated body to General Medical Council UK
Reporting to Takeda VP EU-QPPV and Head of EU Compliance & Marketed Products

Linkin Twitter Website

Bio

Linkin Twitter e-mail Website

Bio

Donald Clark is an EdTech entrepreneur. He was CEO and one of the original founders of Epic Group plc, which established itself as the leading company in the UK online learning market, floated on the Stock Market in 1996 and sold in 2005. As well as being the CEO of Wildfire Ltd. he also invests in, and advises, EdTech companies.

Describing himself as ‘free from the tyranny of employment’, he is a board member of Cogbooks, LearningPool, WildFire and Deputy Chair of Brighton Dome & Arts Festival. He is also a Visiting Professor and Fellow of the Royal Society of Arts (FRSA).

He has worked in schools, vocational, higher, corporate and adult learning, delivering real projects to real learners. These include change management, strategy, tool selection, content design and build.

Donald has over 30 years experience in online learning, games, simulations, semantic, adaptive, social media, mobile learning, virtual reality and AI projects. He has designed, delivered and advised on online learning for many global, public and private organisations. He is an evangelist for the use of technology in learning and has won many awards, including the first ‘Outstanding Achievement in E-learning Award’ and ‘Best AIM Stock Market Company’.

An award winning speaker at national and international conferences, he has delivered keynotes in Europe. US, Africa, Australia, Middle and Far East.

Linkin e-mail Website

Bio

Rob joined CDC’s Direct Equity Investments Team in 2013 to work on private equity transactions in Africa and South Asia. Rob leads on education investments within the overall Consumer Businesses team.

Prior joining to CDC, Rob worked at the UK Treasury. Rob holds an MBA from London Business School, and a Masters in International Studies from the School of Oriental and African Studies.

Linkin Twitter e-mail Website

Bio

Vipul Bhargava leads the Education Technology and Independent Schools practice at UK Trade and Investments. He is responsible for helping UK Education technology businesses and independent schools grow internationally.

As Vice President at EF Englishtown, he was part of the senior leadership team responsible for delivering profitable growth globally. He worked with leadership teams to define strategy and business plans across Latin America (Brazil, Mexico), US, Europe and Asia ( Japan, China, Taiwan). He was also responsible for presenting quarterly and annual plans and results to the board.

Prior to Englishtown, I was at RM Education (a FTSE listed UK education technology company).

Linkin Website

Bio

Ravi Sodha studied in the UK obtaining B.Sc. in Pharmacology, Ph.D. and MBA. He spent several years in Research (London University, Zurich University Hospitals, Ciba Geigy Basel), Clinical Development (SmithKline Beecham) and Sales & Marketing (Novartis). In 1999 Ravi moved to Business Development & Licensing at Novartis, where he spent 8 years in various functions and therapeutic areas. His last responsibility at Novartis was Alliance Management for a Business Franchise and Asia-based job rotation for Business Development activities in the emerging markets, including India, China, Korea and Taiwan. Ravi joined Actelion Pharma Switzerland in 2008 as Senior Director, Business Development, where his responsibilities include structuring and negotiating licensing deals across several therapeutic areas. Ravi has three women in his life, and enjoys cooking, soccer (from the comforts of his arm chair), and spiritual reading.

Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical need. Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma. Founded in late 1997, with now over 2,500 dedicated professionals covering all key markets around the world including Europe, the US, Japan, China, Russia and Mexico, Actelion has its corporate headquarters in Allschwil / Basel, Switzerland. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI). All trademarks are legally protected.

Linkin e-mail Website

Bio

Erik founded Transatlantic Law International in London in 2001 after more than 15 years of international legal and management experience, including in European General Counsel positions for Fortune 50 companies in Brussels and Luxembourg, where he was responsible for all legal aspects of European operations.

Transatlantic has grown under his direction from an original 15 country presence in Europe to a global business law service, serving primarily Fortune 500 companies in multiple countries worldwide.

Erik specializes in global M&A, restructuring, management of cross-border projects, international transactions, global labor and employment law, antitrust, and commercial agreements.

In M&A he has completed or negotiated over 80 major transactions with a deal value of more than $5 billion in every European country and in Asia since 1992, ranging from mid-cap single country acquisitions to billion-dollar cross border acquisitions and joint ventures.

Prior to moving to Europe in 1991, Erik worked as a corporate and litigation lawyer in leading US law firms in Boston and New York.

He has lectured extensively before bar associations and corporate groups in the United States and in Europe on topics including European M&A, corporate governance, distribution and agency agreements, antitrust and compliance programs, and key issues in cross-border movement of executives, as well as global non-competition agreements, among other matters.

He is also senior outside advisor to a number of Fortune 500 companies on executive labor and employment issues including all legal aspects of executive contracts and cross-border movement of executives among his other areas of practice.

He is an honors graduate of Yale University and of the University of California, Hastings College of the Law, where he edited the Communications and Entertainment Law Journal (Comm/Ent), and is a member of the bars of New York and Massachusetts. He speaks French and German and resides in London.

e-mail Website

Bio

David Richardson is the 9th Vice-Chancellor of the University of East Anglia and took office in 2014, after 23 years at UEA. David was born and brought up near Newcastle-upon-Tyne, was educated at the University of Keele (BSc, Biochemistry) and the University of Birmingham (PhD, 1988) and undertook post-doctoral research at the University of Oxford 1988-91. He joined the University of East Anglia as a lecturer in 1991, became Professor of Bacterial Biochemistry in 2001, Dean of the Faculty of Science and Pro-Vice-Chancellor (Research) before being appointed Deputy Vice-Chancellor in 2012 and Vice-Chancellor in 2014.

David was awarded the Society for General Microbiology Fleming Medal in 1999 and is a recipient of the Royal Society Wolfson Research Merit Award. His research group is active in the area of bacterial bioenergetics, and his work has shed important light on the mechanism of greenhouse gas production by bacteria and the molecular basis and function of bacterial nanowires.

David is active in a range of national and regional HE bodies. He is also a Non-Executive Director of the Norfolk & Norwich University Hospital (NNUH), Board member of New Anglia Local Enterprise Partnership, Chair of the Norwich Research Partners LLP and is the President of the Royal Norfolk Agricultural Association for the year 2016-17.

David and his wife Andrea, who also works at UEA as Director of Learning and Teaching, are keen art collectors and enjoy spending time on the North Norfolk coast. Originating from Newcastle, but almost naturalised to Norwich, David splits his loyalties between the Canaries and the Magpies. David and Andrea will each celebrate 25 years at UEA in 2016.

Website

Bio

Virander Paul joined the Indian Foreign Service in 1991. Prior to his assignment as Deputy High Commissioner of India in London, he was Minister(Press) at the Indian Embassy in Washington D.C. Earlier, he has held diplomatic assignments in Indian Missions in Almaty, Vladivostok, Rome, St. Petersburg and Moscow. At the Ministry of External Affairs Headquarters, he has served in Europe East and Americas Divisions. He served as Director in the Prime Minister’s Office during 2007-2010. He holds a medical degree from All India Institute of Medical Sciences, New Delhi.

The areas of potential collaboration between the UK and India were highlighted during the recent visit of the Indian Prime Minister, Mr. Narendra Modi, to the UK.

The UK has a multiplicity of strengths across sectors and is well placed to engage with the ‘Make in India’ initiative.

Dr. Paul added another development is that Indian individuals states are coming to the UK to collaborate and competing with each other. Already 4 states have come so far such as Rajasthan, West Bengal, Odisha and Andhra Pradesh.

On some of the concerns such as more talk and little results, Dr. Paul explained that is short sighted view. He added during last 15 months alone FDI in India has increased by 29%. India is a big country and it may take some time before results show up.

Dr. Virander Paul finally summed up his thought saying India has come a long way from Red Tape to Red Carpet.

First Secretary, T Ajungla Jamir presented Make in India presentation, the idea of 100 smart city project in India with minimum pollution and max recycling.

Dr. Virander Paul, Deputy high commissioner of India to the UK highlighted that

 “Fundamentals of Indian economy remain strong and Make in India is very popular brand now. Make in India is not a single stand-alone initiative but many additional projects such as Digital India, Industrial corridor also along with it. These initiatives are all interconnected and feed into each other”.

 

Linkin Twitter Website

Bio

Keith Krasny is an experienced private practice and in-house lawyer who delivers effective, efficient and practical coaching. Previously, he was Acting General Counsel – UK for AOL UK / Huffington Post UK, and before that VP & General Counsel, EMEA for Expedia in London and Paris for several years. He moved to in-house teams from private practice initially at Weil Gotshal and Manges then Morrison & Foerster LLP.

Keith Krasny is an experienced private practice and in-house lawyer who delivers effective, efficient and practical coaching.

Linkin Twitter e-mail Website

Bio

Colum Elliott-Kelly joined Blippar, the world’s leading augmented reality platform, in 2014 to build a business unit dedicated to the education space. Blippar Education’s vision is to turn the world into an interactive learning environment, layering digital content and tools onto physical space in classrooms, museums, and workplaces.

Alongside his work at Blippar Education, Col is developing a pop-up digital school to help bring education to refugee camps, and offers pro-bono consulting to a range of education and innovation organisations in London. Before joining Blippar, he co-founded and exited Massolit, an e-learning content business, and before that worked in strategy consulting, corporate finance and corporate communications. He is a Governor of the Elizabeth Garrett Anderson comprehensive school in North London.

Linkin Twitter e-mail Website

Bio

FUNKE ABIMBOLA is Managing Counsel (UK & Ireland), UK Data Privacy Officer and UK Company Secretary for Roche, leading the legal team that supports Roche’s pharmaceutical operations in the UK, Ireland, Malta and Gibraltar. She also has a commercial role as England Deployment Lead on a high priority, Roche market access project.

Roche is the world’s largest biotech company.

A practising solicitor for almost 15 years, Funke graduated with an honours degree in law from Newcastle University in 1994. She is qualified to practice law both in Nigeria and in England & Wales.

She is a recognised legal expert within the UK life sciences sector, has received multiple awards and other recognitions for her work and is listed in several international legal directories as an expert in her field.

Importantly, Funke is a notable diversity champion and campaigner within the UK legal industry and has received awards and other recognitions for her diversity work, all of which is done in her spare time on a voluntary basis.

A renowned public speaker, she speaks regularly at legal and diversity conferences in the UK and abroad. She speaks to and advises state school students as part of Speakers for Schools and also supports University students as a Professional Ambassador for Aspiring Solicitors, an organisation devoted to breaking down entry-level barriers for future solicitors from under-represented groups. She is a champion and regular speaker for WILL (Women in Law London), the largest network supporting pre-partnership women solicitors working in private practice and in-house. In addition, she established Women Leaders in Life Sciences law, what is believed to be the first international network dedicated to supporting the pipeline of female lawyer/leaders working within the life sciences industry. She is also personally sponsoring a research-based report on the social mobility issues within the legal profession, due to launch in September 2015.

She is an experienced and expert mentor and sponsor, especially to female and BME students and solicitors. As one of the UK’s leading female pioneers in law, she was recently appointed as a Professional Champion to the First 100 Years project, a ground-breaking project dedicated to building up a digital library celebrating 100 years of female lawyers in the UK.

A proud working mother to a 12 year old son, Funke juggles the demands of her career with home life and advises working mothers on how best to achieve the elusive work/life balance.

Funke is passionate about the law, diversity, education and the healthcare sector. She is also a keen fundraiser for various charities including Cancer Research UK and has twice served as a school governor and a board director.

Linkin e-mail Website

Bio

Raja Dasguta has 22 plus years of experience in Education Sector with special focus on Academia, Institutional Alliances and Skill Development, including at Oracle, NIIT and QAI.

Studenting ERA is a digital ecosystem of student services. Aiding students in their development and career progress quests with a global capability matrix. It is a portal through which allows students to have access to information, services and opportunities which will assist them to enhance their career goals and objectives.

Offerings spanning across five areas of support: Career Counselling services, Global Collaborative Learning Opportunities, Entrepreneurship Development Programs, Project and Employability Program and other student benefits that one can access across any digital devices.

Linkin Website

Bio

Dr. Ajay Agrawal, Ph.D., serves as the Managing Director of the Worldwide organization of collaborations in the pharmaceutical industry, London and Director of business development at Lipoxen Plc, AIM-listed company, in London. Dr. Agrawal serves as a Director of business development at Almac Sciences UK and a Special Advisor on healthcare for commonwealth British council, London. He served as the Head of Business Development for Lipoxen Plc (now Xenetic Biosciences, Inc.) since August 2008. Dr. Agrawal has extensive experience in the biotech & pharma industry worldwide. Dr. Agrawal has almost 20 years’ experience in the biotech and pharmaceutical industry worldwide. He founded PolyMASC Pharmaceuticals plc in 1995. Dr. Agrawal is an entrepreneur and advisor to the number of companies worldwide. He serves on the Editorial Advisory Board of four international biotechnology journals from the USA. He serves as a Director of Manipal Acunova Limited. He serves on the Board of Directors of Clinovo Ltd UK. Dr. Agrawal serves on the editorial advisory board of four international pharmaceutical journals from the USA. Dr. Agrawal served as a Non-Executive Director of ImmuPharma plc from April 27, 2007 to October 23, 2015. He serves on the editorial advisory board of three international trade journals, Current Drug Delivery, Infectious Disorders- Drug Targets and Recent Patents on Drug Delivery and Formulation, Bentham Press, California, USA. Dr. Agrawal has been a consultant to a number of companies in the sector, including Genovac GmbH (Germany), Qiagen (Germany), Aldevron (USA), PHT Pharma (Italy) and Karo Bio (Sweden). He holds a PhD in Chemistry and has conducted his post-doctoral research in the faculty of Medicine, University of Alberta, Canada and at the Royal Free Hospital in London.

Ajay Agrawal is a member in Public-listed Company, Immupharma plc London in London with operations in France and Switzerland. Also, member of the remuneration and audit committees. Won “the New Economy Pharmaceutical & Healthcare Awards for 2010″ for the best European drug development company, and for “best technology award” at the AIM awards, sponsored by PricewaterhouseCoopers Oct 2009. Earlier, also won “Breakthrough of the year award” on our $500 million licensing deal with Cephalon at the “European Mediscience Awards 2009.

Ajay Agrawal is also is an advisory member for Ignite Capital Inc., in relation to the best method to become publically traded, either by IPO, reverse merger or S-1 and 20F Filers. Transactions we have been involved both in the USA and offshore include LBO’s, mergers, acquisitions and restructurings of both private and public companies.Seeking undervalued assets and IP with substantial upside.

He has also participated in a diverse range of financing structures including but not limited to senior and asset based and cash flow debt, mezzanine and convertible debt and common stock/ preferred equity. We provide advices in relation to the most efficient use of capital and have access to a substantial array of capital providers: accredited investors, full service investment banking firms, commercial banks, venture capital firms, fund managers, hedge funds, SBIC’s, offshore funds, PIPE funds, family offices and private equity sponsors.

Linkin e-mail Website

Bio

Lowell is currently the Principal of Dudley College. In challenging economic times, Lowell has led the creation of the multi-million pound Dudley Learning Quarter. This inspirational new town centre campus includes Dudley Evolve, a state of the art vocational centre, Dudley Sixth, a dedicated A level centre and Dudley Advance, a specialist STEM centre (science, technology, engineering and mathematics).

Lowell is Chairman of the college’s Energy Training Hub, a company specialising in the development and delivery of renewable energy and environmental technologies. He is also principal trainer with the college’s Leadership & Management Training Hub, which offers tailored development programmes to senior and middle managers across the public and private sector in the UK and on an international basis.

Linkin Website

Bio

Viren Mahurkar has 25+ year career experience. Senior roles in investment banking and healthcare. Global perspective: New York, Mumbai, London and currently Singapore. Close ties to US, Europe and Asia investor and biomedical ecosystems.

Banking / M&A Advisory roles :

Viren Mahurkar Expertise in M&A, FX/Rates/Capital Markets, Securities Services and Trade Finance. Trained in Macro & Financial Economics, Alternative Investments and Quantitative Finance; establishing linkages between macro-regimes, financial markets & institutions and asset classes in global and key regional economies.

MD HitchinRock Advisors, Singapore
EVP & Head – Strategic Advisory and Capital Markets at ICICI Securities India
Partner/ Head – M&A at Ambit India
Assistant Director, Global Corporate Finance at ANZ Investment Bank London / India
Director/Head – Custodian and Securities Services for Grindlays Bank India
FX/Derivatives Dealer at the ANZ Grindlays Treasury India
Assistant Manager Trade Finance at Citibank India

Healthcare roles:

Thought leadership and operational experience in Healthcare sector. In-house M&A, licensing, strategic alliances and structured deals for 2 majors (PFE, NVS) and 1 Asian family business (WPL.IN). Advisor to several US, EU, JP and Asian large-caps, mid/small-caps, family, private/startup. Strategic and scientific understanding within macro/asset allocation.

Regional Director, M&A/BD&L Asia & Russia for Novartis Alcon, based in Singapore
SVP Global Business Development, Wockhardt, based in India
Director Regional Business Development Europe for Pfizer, based in New York

Academic Background:

MBA from FMS, University of Delhi; MSc from London School of Economics; executive leadership program at Harvard Business School. CAIA and CQF certifications; advanced courses in biotech and healthcare.

Speaker at global and regional healthcare and finance forums

Linkin Website

Bio

Rakesh Roshan is a senior member of the management team at Isis. He is a diligent results-driven senior management leader with over 13 years of experience in technology transfer, technology commercialisation, forming and growing new businesses, developing investment strategies and roadmaps, and implementing innovative management policies. Rakesh has extensive accomplishments in motivating and providing strategic guidance to negotiate, execute, and manage complex licence and spinout transactions. He has a strong track record in evaluating, structuring and securing investments for various business propositions that resulted in the formation of a number of technology companies. His proven leadership proficiencies involve directing diverse and cross-functional teams to deliver commercial objectives on time and within budget.

Under his leadership, his team at Isis Innovation has formed more than 15% of all Oxford spin-outs to date and secured equity funding from leading private and institutional investors based in USA, Hong Kong, Japan, China, India and the UK.

His Areas of excellence will be: International Partnerships, New Ventures, Emerging Technologies, Open Innovation Strategy, Technology Roadmap, Investment Decisions, Procuring Investment Pipeline, Due-diligence, Strategic Alliances, Raising Capital, Financial Modelling, Technology Evaluation, Business Development, Business Planning, Contract Negotiations, Business & Risk Analysis, Leadership Skills, Team Management, R&D Management, IP Management, Technology Commercialisation, IP Landscaping and Litigation. .

Linkin e-mail Website

Bio

Satyendra Shrivastava is a corporate generalist and he leads the regulatory insurance, employment, global mobility at Khaitan Legal Associates. He regularly advises clients on entry strategies and on various aspects of doing business in India and has an extensive experience of working with different regulators in India.

He is a frequent speaker at international conferences and seminars on different areas of Indian law and regulation and also facilitate training and workshops on HR law and general regulatory framework for foreign companies interested in establishing a presence in India.

Linkin Website

Bio

Chris Oglesby grew up in Manchester from the age of four, attending Cheadle Hulme School, before studying at the London School of Economics and City University, London. He graduated with a BSc (Hons) in Property Valuation and Finance and joined the investment team in the City of London Office of St Quintin (now CBRE), before returning north to work for Bruntwood in 1991. He qualified as a Chartered Surveyor in 1993 and set up Bruntwood’s Manchester city centre office, adding an in-house sales and marketing team, before taking over the reins of the company as CEO at the end of 1999.

Chris Oglesby’s company is a family-owned and run company, Bruntwood has always operated with a strong set of values, founded on its belief that the success of the company comes from the success of its customers and the communities in which it operates. This commitment to cities has led to Chris playing an active and often leading role in many public and private sector initiatives and partnerships. He has been a board member at CityCo (Manchester’s city centre management company), the Piccadilly Partnership, Corridor Manchester (the city’s major knowledge economy initiative focused on its universities and hospitals) and the Irwell City Park initiative along the boundary between Manchester and Salford. In Liverpool and Leeds, he has taken his experience of best practice in local area partnerships and instigated the set-up of the Commercial District and West End Partnerships respectively in each city.

Bruntwood is nationally recognised for its support of cultural and community initiatives, donating 10% of its annual profits to charitable causes. Chris is a Trustee of The Oglesby Charitable Trust, which works with more than 40 community based charities a year, and is a board member of Onside, a new charity which is developing a series of youth centres across the North based on the successful Lads and Girls Club model pioneered in Bolton.

Chris has a strong belief in continued personal development. He was a member of the Academy of Chief Executives from 1998-2002 and has been a member of the Young Presidents Organisation since 2000, holding several officer positions over the years including Chairman in 2007/8. He also attended the Owner President Management Programme at Harvard for three years, graduating in 2007.

Chris Oglesby, Bruntwood CEO and MSP Chairman, said:“Through our acquisition of Alderley Park, we have a unique opportunity to create a diverse innovative community of bioscience businesses which is internationally respected for the quality of its work and as a sustainable business model. With our partners and the community of exceptional scientists who choose to remain at the Park, we will build a flagship for a vibrant life sciences industry in the North of England.”

Website

Bio

Dr. Prem Bajaj is currently Medical Director of Modern Health Limited, London. He completed MBBS from Delhi University,  India, has a Fellowship of the College of General Practitioners, India, Doctor of Medicine (Copenhagen University, Denmark) Ph.D. in Pain Management (Alborg University, Denmark), Masters in Clinical Pathology and Immunology (Sheffield Medical School, UK), Masters in Pain Managment (Wales School of Medicine, Cardiff, UK) and Certifications in Medical Acupuncture and Hypnotherapy from UK. He has published articles in several international journals and is an honorary reviewer for several peer review journals. He has won several scholarships and awards during his career.

Dr. Prem Bajaj is a medical practitioner specialising in pain management, clinical pathology, acupuncture and hypnotherapy. His approach to patient management is holistic and he also incoporates medical acupuncture and CBT-hypnotherapy into the management where appropriate. He subspecialises in managing fatigue syndromes, deaddiction, chronic diseases including fibromyalgia, Lyme disease and multiple chemical sensitivities. He has also gained broad, multi-speciality experience having worked in the departments of Neurology, Orthopaedics, Medicine and Pathology in large hospitals in Denmark and India. He has done his post-doctoral clinical research from the department of Addiction Pharmacology, San Francisco, USA .

Dr. Prem Bajaj is fluent in English, Danish, Hindi and Punjabi.

Dr. Prem Bajaj’s special strengths are that he is able to establish a special comfort zone with his patients and reaches the depth of their problems, providing them appropriate treatment and educating them to follow the principle ”prevention is better than cure”. His approach is full of empathy, sympathy and is non-judgemental.

His values are that he is truthful, honest and delivers with self clarity. He is an academic researcher, an expert in conducting clinical trials, a social worker, author, reviewer of scientific publications and also possess an indepth knowledge of drug development, drug safety and Good Medical Practices.

My Vision: To use my broad spectrum medical and clinical skills in the prevention and management of complex diseases and bringing goodness, happiness, good health and peace to all.

Linkin Twitter e-mail Website

Bio

Janvi is the Chairwoman and co-founder of Halebury. Janvi focuses on client management and business development as well as team building and management.

Halebury is an alternative law firm and NewLaw pioneer. Our flexible model provides a range of resourcing solutions to our clients and a unique career path for senior in-house lawyers. Our expert legal consultants have held positions as senior in-house counsel, Heads of Legal and General Counsel in leading businesses; they have the experience and commercial skills to seamlessly integrate with your legal team and business and to hit the ground running. With a strong TMT and financial services sector focus, we partner with you for the long term to help identify your resourcing challenges and seek to genuinely add value by creating new systems and efficiencies.

Halebury lawyers are “your external in-house lawyer”. This concept is achieved by focusing on three key ingredients; engaging lawyers with superior industry knowledge and strategic focus; retaining entrepreneurial lawyers; and creating an innovative legal services model. Halebury lawyers specialise in employment, commercial and corporate law within the technology, media, telecoms and financial sectors.

Linkin Twitter Website

Bio

Simon Wallwork is a Partner in the Corporate Finance team at Slater Heelis LLP in Manchester.

Simon Wallwork key strengths is his ability to develop close working relationships with our clients. Our work is strongly partner-led and our service combines technical expertise, sector knowledge, commerciality and risk assessment. We pride ourselves on the quality and speed of our delivery of advice, our innovative thinking and commercial awareness and our availability to our clients.

We advise on:

(a) mergers and acquisitions of companies and business assets ;

(b) Venture Capital funding;

(c) public-to-private transactions, MBOs, MBI’s and IBO’s;

(d) IPO’s, Public Offers, Placings both public and private;

(e) refinancing, debt restructuring and corporate reorganisations;

(f) general advice on corporate structures, share buy backs, corporate governance, joint ventures.

We have expertise in the Life Sciences, Renewable Energy and Technology sectors giving us a thorough understanding of the issues and pressures affecting businesses in these sectors.

Specialties: acquisitions, disposals, MBO’s, MBI’s, IBO’S, Listings on AIM, and other markets, joint ventures, development capital, private equity, corporate governance in particular in the Renewable Energy, Life Science and Digital Technology sectors.

Linkin Website

Bio

Roger New is a Scientist/inventor with 40 years experience in the biotechnology/pharmaceutics area. Professional interests:oral drug delivery, oral vaccines, drug discovery, peptide therapeutics.

• Thirty years experience of  Research and Development in field of  drug delivery
• World-recognised expert in liposomes:  author of seminal reference book “Liposomes – A Practical Approach” published by OUP
• First to demonstrate efficacy of liposomal amphotericin.  Coordinated first Phase I/II trials of liposomal doxorubicin
• Devised three new systems for oral delivery of insulin, giving first positive human results ever observed in Type I diabetics
• Honorary professor at several foreign academic institutions.  Consultant advisor to IRCD.  Member of UK Govt Expert Mission on Biotechnology to China and Brazil
• Patent applications filed and granted in areas of pharmaceutics, diagnostics and microbiology
• Inventor of Patents
• Frost & Sullivan European Entrepreneurial Company of the Year Award in Diabetes 2011
• Finalist TechMARK Emerging Star 2012

Website

Bio

Richard Cruse entered the biotech industry in 1987, as Director of Finance with Delta Biotechnology, and, until joining Entomed SA in April 2002, was Finance Director with PPL Therapeutics PLC for the previous 9 years. During this time, PPL concluded a number of VC and pre-float investments and established a full listing on the London Stock Exchange with a further two follow-on offerings. Richard was also closely involved in the execution of a complex financing package intended to facilitate PPL’s manufacturing plant construction and crucial to the final rights issue. As well as the position of CFO, he held responsibility for the business development function at Entomed, involving the conclusion of research collaboration agreements and marketing of compounds for out-licensing. Prior to entering the biotech industry, Richard’s career was based in manufacturing. He is a Chartered Certified Accountant and has an MBA from Sheffield Business School.

e-mail Website

Bio

Mr. Julien Machot is currently the Chairman of ISDC Global and an Investment Banker with at EFG Bank Headquarter in Switzerland having operations across Europe. His name is well known in the Private Banking Sector and Global wealth Management. He is a dynamic and vibrant entrepreneur and also a visionary in Education Sector.

Julien holds a Double Masters from University of Paris in Economics and International Business. Julien Machot has worked as the CEO of Sloane Group and also the Director of LSBF (London School of Business & Finance). He was also the Treasurer and General Secretary at CIG, The CIG is the prominent reference among UHNW investors in Europe, in Switzerland and throughout the world.

e-mail Website

Bio

Jane is currently Head of University Development, ACCA. She graduated from Exeter University and started her career as a Chartered Accountant with Ernst and Young, London. She went on to work as a lecturer in accountancy in Singapore and as an auditor in Australia before returning to the UK and going on to become Head of Accounting Finance and Economics at Oxford Brookes University. She is co-author of the text book ‘Accounting: A Smart Approach’ and has a Doctorate in Education from the Institute of Education, UCL.

Twitter e-mail Website

Bio

Karl Chapman is Chief Executive of Riverview Law and has a long pedigree in starting, growing and managing successful companies.

After reading law at Birmingham University, Karl joined Guinness Mahon Investment Management (GMIM) in 1985. In 1987 he was Money Observer’s top-performing UK unit trust fund manager.

He left GMIM in 1989 to set up CRT Group plc (CRT), a consultancy, recruitment and training business. Under Karl’s leadership his team grew CRT, both organically and by acquisition, to a market capitalisation of over £600 million, sales in excess of £400 million with 2,500 employees operating from over 200 locations. In 1996 CRT sold 50.1% of its equity for £109 million to Knowledge Universe, a private US-based company whose major shareholders were Larry Ellison and Michael Milken.

Karl left CRT in 2000 and set up AdviserPlus Business Solutions in 2001. AdviserPlus is a leading advisory outsourcing organisation providing HR, and H&S solutions to organisations ranging from FTSE 100 companies to SMEs. He joined Riverview Law with effect from 1 June 2011.

Karl is excited by the changes taking place in the legal market: “Rarely do market opportunities like this arise. The legal market is large, fragmented and has few brands. New entrants like Riverview Law, with no baggage and a total focus on the customer, stand a very good chance of building big and sustainable businesses.”

Karl is based in London and Lincolnshire and couples his passion for business with a long-standing love of Chelsea Football Club where, over more than forty years, he has experienced the lows and highs that come with an irrational attachment to a football team.

Bio

Dr. Ann Van den Bruel research focuses on diagnostic tests. Diagnostic tests help doctors to identify illnesses and other conditions so that patients may be treated or given a prognosis about the course of the illness. It is important to study the added value of tests because a better understanding leads to more efficient healthcare and better outcomes for patients.

Over the past years, Dr. Ann Van den Bruel have worked mainly on the diagnosis of serious infections in children. More precisely I conducted a large-scale study in primary care to analyse the value of clinical features for this diagnosis. In addition, we looked at how laboratory tests can help with this diagnosis and how parents and doctors view the diagnostic process when a child is admitted to hospital with a serious infection. The results of these studies have been used in several guidelines including one on feverish children by NICE.

More generally, I have collaborated with colleagues in other studies on diagnostic tests, such as clinical features in patients with chest pain, ultrasound for patients with shoulder problems, exercise testing to identify coronary disease, etc.

Currently I am the Director of the NIHR Diagnostic Evidence Co-operative Oxford which aims to facilitate diagnostic innovations in the NHS. We offer training and advice for anyone who is developing a new diagnostic test for primary care.

In addition to research, I’m also involved in teaching for the Centre for Evidence Based Medicine and other institutions across Europe.

Linkin e-mail Website

Bio

As Executive Vice President – Academics, Dr Noel Tagoe oversees the formulation and implementation of CIMA’s research strategy, the development of CIMA’s qualifications and related assessment. He was previously Head of Research and Development at CIMA.

Prior to joining CIMA Noel taught at University College Dublin (UCD) in Ireland and the universities of Manchester, Reading and Oxford in England. Between academic appointments he held senior accounting and strategy positions with BP and Elf Aquitaine (now part of Total Oil) in Africa. In addition, Noel established and led KPMG’s financial advisory consulting practice in West Africa for 3 years.

Noel is a chartered accountant from Ghana and a fellow member of CIMA. He holds an undergraduate degree from the University of Ghana and postgraduate degrees from the universities of Dundee and Oxford.

Linkin Website

Bio

Mark Birse is the Group Manager for the MHRA Inspectorate which comprises of over 70 Inspectors covering GCP, GDP, GLP, GMP & GPvP. Mark is eligible to be named as a Qualified Person and is a chemistry graduate with an MSc in pharmaceutical sciences. He is also a Fellow of the Royal Society of Chemistry. Prior to joining the MHRA in 2002 as a GMP Inspector, Mark previously worked in the pharmaceutical industry for over 10 years in a variety of roles including process technology, technology transfer, new product introduction and quality assurance.

Mark Birse is a member of the PIC/S Executive Bureau through his chairmanship of the Sub Committee on Communications.

Providing leadership for the Inspectorate and driving forward collaborative working with other Government departments and international regulators, including building international cross-border confidence and seeking opportunities for synergistic working and resource sharing.

Ensuring that adequate Inspectorate resources are provided to both enable a robust and proportionate inspection programme that is established on risk based methodologies whilst also supporting external meetings and EU and International initiatives. For example implementation of new EU directives, EMA Inspectors Working Groups and their associated drafting teams for changes to EU legislation, PIC/S Committee meetings and Expert Circles, OECD and Council of Europe.

Being a member of the Inspection, Enforcement and Standards Division Leadership Team.

Seeking opportunities to foster and support innovation through creating a more enabling regulatory environment for the adoption of innovative manufacturing technology and supporting development activities through a risk adaptive approach to clinical trials.

Presenting and chairing sessions at numerous UK and international conferences and meetings on a range of MHRA and Inspection issues.

Linkin e-mail Website

Bio

Morten Hagen has a Masters degree in Mechanical Engineering from UCL and an experienced strategy consult in the FMCG sector at P&G and Unilever. He loves technology and is driving growth at SAM Labs.

SAM Labs is a rapid development kit for the IoT which makes designing and setting up Internet of Things applications fun and easy. Morten will be representing SAM Labs as one of the IoT Forum’s Ones to Watch this year.

Linkin Twitter e-mail Website

Bio

Tonee’s passionate about technology and the opportunity it provides education in the developing world. A dyslexic learner. Love learning and technology. Intrigued by the combination of both. Tonee dislike how we learn. Most dyslexic people do.

A Social EdTech-prenuer building an education innovation that advance students in Africa while making a sustainable business model for education stakeholders. Adventures in his previous life: Founder of the largest IT incubator in Kenya, raised €5 Million for it. Current adventure: Building Kytabu( org), a textbooks subscription application for all desktops and laptops as well as android tablets for the developing world.

Beating the OLPC model with a big stick…it can be done better. Kytabu is an android application for phones and tablets that enables teachers and students to rent curriculum textbooks using mobile money. Kytabu leases textbooks as chapters, pages or complete books for either an hour, day, week, month or school term.

This fractured size and varied time reduces the cost of the content buy 72% and in some cases, by 1/1000 of the original price.

e-mail

Bio

Richard Tapp, Director of Legal Services for Carillion, has been named one of the top lawyers in Europe by the influential FT Innovative Lawyers 2013 Awards. Carillion plc is a major player in the business services and construction fields, with revenues in excess of £4bn and more than 50,000 employees, and an in-house team of some 20 lawyers focusing on the provision of innovative business solutions. He is the co-author of Managing External Legal Resources (ICSA Publishing).

Linkin Twitter e-mail Website

Bio

Tom’s Hooper second venture in education technology is Third Space. He is passionate about the role technology can play in helping solve social problems. Tom spends his time building support for Third Space from grassroots to Government level. Third Space Learning connects teachers from around the world to children in schools across the UK, to provide live one-to-one maths support during the school day for children at risk of failure. Third Space was launched in 2013, and has established three academic centres in Asia – two in India, one in Sri Lanka – where local maths graduates are trained to be specialist online teachers, connecting to children in English schools via Third Space Learning’s online teaching technology. As an EdTech company that has built the foundation of its model in India, He is excited to be speaking at IEIC 2016.

Linkin Twitter e-mail Website

Bio

Under Selva’s leadership Regent Group was nominated for three industry awards as an award finalists by Education Investor in the categories: Education Business of the Year 2014, Higher Education Provider of 2014, Private Tuition Centre operator of 2014 Selva is in the process of launching Regent Leadership Academy in London and the United States with his management and thinking guru from Harvard University – Prof. Huete is mentoring Selva with the launch of Regent Leadership Academy in early 2015 with a view to nurture leadership in a very unique manner via managing and resolving conflicts Recently Selva has been instrumental in launching Regent English Academy to support the local linguistic needs of North West London’s incredibly diverse and cosmopolitan student population.

Linkin e-mail Website

Bio

Sam Barton is a Business development Manager helping businesses to mature from start-up upwards. Special Advisor to HRH The Duke of York, KG supporting iDEA and Pitch@Palace initiatives.

Global Sales & Markets group – Supported EXCO reporting requirements, worked on Gamification piece. Global People Performance and Culture group – Project Manager for Global Purpose roll-out. Restructuring: Key engagement, MF Global UK Limited (In Special Administration) working on inter-company loans, resolution of client asset positions (segregated and non-segregated), damages claims, debtor reviews and London Metal Exchange client account reconciliation.

Linkin Twitter e-mail Website

Bio

Ravi Dugal, President of Flipick Pvt. Ltd. (www.flipick.com), a self-catering online service that allows publishers and design shops to produce their own fixed-format eBooks directly from within Adobe InDesign.

Flipick is a technology-based partner that provides interactive, real time, self-paced ecosystems for learning and managed technical services. It helps create an immersive environment that is conducive to conceptual learning. Flipick delivers a 360° solution for the educational industry that includes content digitisation, re-authoring, interactive designs, game based eLearning, assessment and detailed analytics as well as content delivery on web, iOS, Android and Windows 8 platforms.

Some of the services include:

₋ Technical Need Analysis

₋ Building interactive content for higher education

₋ Authoring content for HTML5 based 2D/3D animation

₋ Re-authoring animations from Flash to HTML5

₋ Video production and enhancementsFounder Abacus Computers Limited the first in India to pioneer a revolution for open platform language publishing and newspaper editorial system in the eightees

Other experiences;

CEO of Mediawide group of companies. Pioneered self service real estate advertising solutions for UK newspapers almost 8 years ago. Solutions are used in leading newspapers today, one of the newspaper chain building almost 4000 broadsheet real estate pages every month

Architect of Brandmark, a unique solution for localized marketing for leading brands. Brandmark comprises media planning, ad building, automated adaptations, approvals management and electronic delivery. Leading brands including Singapore Airlines, Standard Chartered Bank, Hyatt, Monsanto, Goodyear, Shell and Wriggleys use the solution to build print ads, catalogs, flip books, web banners and visual merchandize

Vertical solutions of Brandmark include workflow and FSI (circulars) builder with full support of versions for regional promotions

Mediawide is actively involved in consulting and bespoke development around web to print, VDP, database publishing and integration with ERP systems

Specialties: Dynamic publishing, editorial systems, advertising solutions, brand marketing operations management and language publishing

Linkin Twitter e-mail Website

Bio

Rajay Naik was previously the director of government and external affairs at The Open University (OU) – the U.K.’s largest university and a global leader in online learning – Naik now leads Keypath’s European operations and is based out of its London office. During his time at The OU, the institution has continued its domination of adult education, grown its international partnerships and launched the FutureLearn MOOC platform.

Naik is a major figure in U.K. higher education, joining senior ministerial delegations on behalf of the British government and as a member of the high-level UK-ASEAN Business Council. Before joining The OU, he was a member of the landmark Independent Review of Higher Education, chaired by former BP CEO Lord Browne. As far back as 2006, he co-authored “Learner Voice,” which examined how technology would transform education. In May, Naik stepped down after six years as a non-executive director at the Big Lottery Fund where he managed a £1.7 billion per year budget as chairman of U.K. funding. He also recently served on the U.K. Digital Skills Commission and the Department for Business, Innovation & Skills’ Education Technology Action Group.

Linkin e-mail Website

Bio

Paul Balogh (CEO) and Cristian Dinu (CTO) – cofounders of Learn Forward, a UK startup focused on making the digital classroom work by using real-time technologies to power two-way communication in tech-enabled classrooms (delivery of content but also collaborative work). Both cofounders are originally from Romania and they pack different backgrounds: Paul was involved with the publishing sector managing digital businesses in this space while Dinu has a strong background in designing IT solutions for large corporations such as IBM and Vodafone. They decided to move to the UK in 2015 after being winning a place with a London-based business accelerator specialised in EdTech: Emerge Education.

Linkin Twitter e-mail Website

Bio

Kevin McCole joined the UKIBC in December 2008 as Chief Operating Officer and has a range of responsibilities: co-ordinating the work of the team across the UK and Indian offices; directly leading the Membership, Consultancy, and Policy and Research teams; and managing relationships with members, UK Trade and Investment and other stakeholders. Kevin also serves on the British Chambers of Commerce’s Global Accreditation Board, and on the UK’s Overseas Business Network Partnership Board convened jointly by the Foreign and Commonwealth Office, UK Trade and Investment and the British Chambers of Commerce. Kevin joined the UK India Business Council after 19 years in the UK’s Diplomatic Service, where he served in The Netherlands, Malta, Romania, India, and various London postings. In India, Kevin spent three years at the British Deputy High Commission in Kolkata helping UK businesses win contracts and find partners in Eastern India and assisted Indian companies expand into the UK.

Facebook Linkin Twitter e-mail Website

Bio

Trevor Barratt is the Managing Director – TES Global

• Highly experienced media professional and owner with over 30 years’ experience managing content and event related assets.

• Twenty years’ experience at board level, with the majority as CEO

• Managed and sold two businesses via leveraged buy outs. In addition, made numerous acquisitions a and disposals of individual assets

• Extensive knowledge of digital media though events and publishing

• Key strengths are: strategy – in particular event dynamics, content led media and sales proposition, leading to the routes to extract maximum shareholder value.

Passionate about social housing, sport (rugby, golf, cricket and squash). Member of Harlequins Rugby Club and the Nevill Golf Club.

Linkin e-mail Website

Bio

Isabel Newman supports all stages of the investment process from initial appraisal through to deal execution and portfolio management, with a specific focus on the fund’s Children and Young People theme.

Isabel has a background in social investment and international grant making, having previously worked at CAF Venturesome and Comic Relief.

She holds a BA in Geography from Newcastle University and an MSc in Globalisation and Development from SOAS.

Isabel is also a Trustee of The Midi Music Company, a south London based charity that inspires children and young people to get into the music and creative industries.

Linkin Twitter e-mail Website

Bio

Gurpreet Jagpal is an inspirational, transformational and visionary Director with the proven ability to transform business performance: managing and implementing change, delivering operational efficiencies and providing measurable results. Introducing strategies, turning ideas into reality and acting as an ambassador for business culture, branding and philosophy – promoting visions and values.

Championing strategies in entrepreneurship, business support, training, engagement and company creation I enjoy taking ownership of multiple project delivery, managing staff and funding, delivering measurable results & instilling a performance culture. Financially astute Gurpreet lead on controlling and planning departmental budgets, forecasts and reporting structures.

e-mail Website

Bio

Dame Asha Khemka OBE DBE joined Council in 2009 and is also a member of Finance Committee. She took up her post as Principal and Chief Executive of West Nottinghamshire College in May 2006. It is now one of the largest colleges in the country with just over 30,000 students and an annual budget approaching £70 million. The College, as an organisation, and Dame Asha, individually, have received public recognition and acclaim for their contribution to the Further Education sector and for their contribution to the ex-mining communities of North Nottinghamshire. Dame Asha’s lifetime contribution to the sector was recognised in 2009 with the award of an OBE and again in 2014 when she became the first Indian in living memory to be appointed a Dame Commander of the Order of the British Empire. Dame Asha is a board member of several national organisations, including the Association of Colleges (AoC), being the Chair of its Quality and Performance Portfolio Group and Chair of AoC India. She is a board member of the Education and Training Foundation, D2N2 LEP and is a Trustee of City and Guilds. She is a founder member of the Inspire and Achieve Foundation whose main objective is to raise the aspirations of working class young people.

Linkin Twitter e-mail Website

Bio

Christine Major has more than 15 years of experience in the ed tech industry and has worked from Governments in Asia to classrooms in Canada. As Director of Global Solutions for Discovery Education, Christine cultivates deep partnerships with education partners, to develop customized solutions that support their strategic goals and help make the transition to digitally enhanced teaching and learning. A former UK primary teacher, Christine has led the UK’s largest technology focused professional development service for schools and her talks blend humor, deep insight and a wealth of global experience.

Linkin e-mail Website

Bio

Charles’ McIntyre experience has been in building businesses in a number of industry sectors including: financial services, media, media tech and more recently online education. He co-founded IBIS Capital in 2003 in order to create a flexible, boutique investment bank that could both invest in, and advise companies and their shareholders. 12 years on and IBIS Capital has evolved into three distinct businesses; investment banking, venture capital and hedge fund management. Charles also sits on the Boards of a range of entrepreneurial companies in the media and education sectors.

Charles began his career with the investment banking arm of Apax Partners, one of the leading independent private equity firms in the UK where he helped build the company’s media franchise. In 1998, together with other senior management, Charles spun off the investment banking arm of Apax Partners. Over the next two years the business was built up into a pan-European investment bank operating with offices in 7 countries with 140 people. Charles was the Managing Director responsible for European media investment banking and was involved in a wide range of fundraising and M&A transactions.

In 2003, Charles joined David Forster to form IBIS Capital. Now in its 12th year IBIS Capital has established itself as a leading investment banking boutique focused on the media and media tech sectors with over 50 corporate transactions completed. The company is also able to act as a principal investor both in the public and private markets. In 2013, Charles started focusing on the e-learning and edtech markets and is responsible for a number of key industry initiatives including co-founding EdTech Europe, an annual summit for strategic players and investors interested in the online education market.

Specialties: Media and Ed-Tech Investment Opportunities Business Deals in the Media, Media Tech and Ed-Tech Sectors Mergers and Acquisitions

Linkin Website

Bio

Dr Rajay Narain is a Research Cardiologist at St George’s University Hospital, London UK.

Dr Rajay Narain has been instrumental in designing the Foundation training program for Junior Doctors in the West Midlands in the UK. He has also lead MRCP exam teaching at various UK hospitals.He has been performing Coronary angiograms, echocardiograms & doing pacemakers independently as part of his training. He also runs Inherited Heart Diseases clinic at a University teaching hospital in London. He has also been associated with coronary angioplasty programs at UK’s two biggest Heart Centers.

Dr Rajay Narain has been involved in Heart Screening programs since 2005 at National & International level; he has also been screening UK Football & Rugby league players. Dr Narain while pursuing his career in Cardiology in UK also set up first of its kind of Foundation for the underprivileged in India. Dr Narain was appointed as Founder Member of International Development Group of NHS, UK & Director, Heart Foundation, UK in recognition of his contribution to International Health arena. He is also Advisor to many Government and Private Medical Institutions in India. He has presented papers at several National & International Conferences. He has to his credit publications & research projects in Cardiology which have been published in different medical journals.

Cardiologist with expertise in:
Executive Health and Heart Screening
Sports Cardiology
www.heart-matters.net

Director
Global Health Alliance
(Up-to-Date Certified Health Education & Training Courses for Health Professionals in UK & Worldwide)

Global Health Alliance is an initiative which is aimed at delivering up-to-date short accredited courses and programs for health professionals. The team consists of experts from renowned universities and hospitals from across the UK. The courses are meant for doctors, nurses, specialist nurses, paramedics, cardiac physiologists & general public.

Linkin e-mail Website

Bio

Saswata Mukherjee has worked for Unilever Legal group since 2002 working in several portfolios worldwide. Currently based in London at head-quarters, Saswata is part of Unilever’s Legal Management Team as Global Legal Operations Director.

He is responsible for external legal provider strategy and implementation including law firm panels and legal service provider strategy. Saswata is also overseeing Unilever’s Legal transformation agenda and ensuring the talent pool has the right learning tools by creating a learning academy. The role also is responsible to drive simplification and IT synergy and opportunities for the entire legal group, including contract management and matter management tools.

Previous to this role, Saswata was Legal Director SEAA (South East Asia Australasia), overseeing the cluster and involved in all issues/key projects most notably M&A’s. Saswata also led the Competition Law work for Unilever in Asia (South Asia, North Asia and SEAA) and was the Customer Development legal business partner.

Saswata also acted as Legal Director (Board member) for Unilever Asia Pte Ltd (Unilever’s office in Singapore) leading a team of lawyers managing all legal & compliance issues. Saswata moved to Singapore in 2007 to undertake a specialised Supply Chain Legal Business Partner role and thereafter moved to corporate commercial roles in 2011.

Initially he was based in the operating company (Hindustan Unilever Limited) and went on to take on numerous roles. The roles entailed business partnering CD, Marketing and Supply Chain functions (factories) and accountability for litigations dispute management in India.

Saswata wants to spend his spare time with his family and travelling to different countries. Saswata is also an avid football fan.

Linkin Twitter e-mail Website

Bio

Maniti Barot is a Director with Pangea3 and is currently responsible for managing client relationships arising out of Asia-Pacific and Europe. In this role, Maniti works with clients on a wide range of engagements, leveraging her hands-on, unparalleled expertise in offshore project management. Her experience as a practicing attorney allows her to provide consultative project guidance to clients across Asia-Pacific, helping legal departments and law firms take advantage of time and cost-saving legal services and solutions.

For over 8 years, in her previous position with Pangea3, Maniti was responsible for managing a team of attorneys within the Corporate & Compliance Department. In that role she ensured the consistency and quality of reviewed contracts, contracts negotiations, contract abstractions and oversaw all aspects of client interaction. She endeavoured to meet her client’s expectations and maintain the highest quality and efficiency by using Six Sigma methodologies, playbooks and other knowledge objects.

Maniti received her law degree at Government Law College and is a member of the Bar Council of Maharashtra and Goa in India, with all India practice rights. She also is a certified Six Sigma Yellow Belt.

Linkin Twitter e-mail Website

Bio

Glenn Quadros has both a deep strategic and practical perspective on outsourcing and shared service issues having over 10 years’ experience on the “buy”; “sell” and “ultimate customer” side. He is also a very active NOA founding member.

Highlights include:

Currently, sitting on the board as General Counsel of ETS (“Enterprise Solutions and Technology”) Unilever – one of the largest, most progressive and sophisticated shared service organisations in the world. A key focus areas here is driving greater value from strategic suppliers, especially as service is predominantly delivered through suppliers, with 2/3 of spend being with third parties.

7.5 years on the buy-side at BT Global Services – experiencing both periods of high growth and challenging down-turns, where there was a significant amount of introspection on what went right and what went right. Helping to transform the legal function supporting ETS by initiating alternative methods of sourcing legal services. Three objectives of particular focus of Glenn are helping to: Reposition and rebrand the NOA to help influence the media, end users and suppliers on promoting the benefits of outsourcing arrangements. Ensure that End Users interests are at the heart of all key debates. Develop conventions “sticking” areas between “buyers” and “sellers” to promote a speedier, more effective and ethical way of transacting.

Linkin Twitter e-mail Website

Bio

Aldo de Pape is a strong believer of opening science and education for the betterment of society. Aldo previously worked at Springer and Digital Science, a corporate venture capital fund of Macmillan Publishers investing in scientific technology.

Aldo was trained in Utrecht and Gent and has a Masters degree in International Relations and General Management. In 2007 Aldo published I am! (a children’s book). TeachPitch is a web-based platform that helps teachers and schools identify the best online learning resources. We would love to hear your ideas and feedback on our new product TeachPitch for Schools, a repository technology that helps individual teachers, departments, schools and districts find, share, manage and monitor the very best of learning.

Linkin e-mail Website

Bio

Abhijit Mukhopadhyay has done Graduations in Commerce (Honours) and Law from India and the UK. He is a qualified Company Secretary from India and Chartered Secretary from the UK and is a Fellow Member of The Institute of Company Secretaries of India and The Institute of Chartered Secretaries and Administrators, UK.

Abhijit worked in India as Head of Legal and Company Secretary in six big public and private sector / multinational companies as Chief General Manager, Director and Senior Vice President (one step below Board level). Currently working as the President (Legal) and Company Secretary in Hinduja Group in London, ,Abhijit is involved in the Group’s worldwide legal matters covering international mediation/ arbitration, international litigation, strategic alliances, compliance of international sanctions, corporate governance and Board / Shareholder related issues, Intellectual Property Rights, M&A, negotiating international contracts, company structuring, Joint Ventures, anti-competition, etc. Abhijit was Company Secretary of a listed limited company in the UK and is a non-executive Director in Companies in five countries (Hinduja Group is a USD 15 billion Group with 80,000 people in 40 countries engaged in automobile, foundry, lubricant, power, banking, healthcare, defence, chemicals, explosives, media and BPO, thro’ its listed public and private companies). Abhijit is involved with many international organizations in various capacities as detailed below. Abhijit speaks in many international seminars globally and has written many articles in reputed international magazines.

In India, he was associated with the activities of apex Chambers of Commerce as Committee Members, Member of the Secretarial Standards Board of The Institute of Company Secretaries of India and was in the Guest Faculties of several Indian Universities. In 2010 in India Abhijit was listed as one of the top 50 legal professionals and in 2013, he was a nominee of Global General Counsel of India award.

Linkin Twitter e-mail Website

Bio

David Williams is a commercially-focused legal adviser and business partner to senior management across broad range of issues and projects. His responsibility also includes in  business transactions, regulatory and compliance matters, and litigation/dispute resolution, with a focus on pharmaceutical/lifescience and highly-regulated consumer goods sectors.

Specialises in contract drafting and negotiation; mergers and acquisitions; general commercial legal advice; marketing and promotional issues, regulatory and compliance

Manager of a Legal department operating in UK, Ireland and Mumbai, providing legal advice and compliance guidance to a business operating in over 100 countries.

Concordia International specializes in the acquisition, licensing and development of off-patent prescription medicines, which may be niche, hard-to-make products. Its medicines are manufactured and sold through an out-sourced manufacturing network and marketed internationally through a combination of direct sales and local distribution relationships. The company’s diversified product portfolio consists of approximately 200 molecules, representing a variety of dosage strengths, formulations and geographic markets and covering a range of therapeutic categories, including endocrinology, neurology, ophthalmology and urology.

He was responsible for team of lawyers providing legal and business advice to Teva’s business operations in UK, Ireland and Nordics.

Linkin Twitter e-mail Website

Bio

Alex Hamilton is a co-founder and Chief Executive Officer of Radiant Law. Before founding Radiant Law, Alex was a Partner at Latham & Watkins and co-Chair of Latham & Watkins’ global Technology Transactions Group.

Alex is recognised in Chambers & Partners and Legal 500 as a ranked expert for IT and for outsourcing, with clients saying: “he takes a modern approach – he listens and understands the problem first, and is very cost-efficient”, “first choice lawyer”, “impresses everyone he comes across”, “In big-ticket outsourcings you want a pretty robust contract to draw on, and that’s what Alex always delivers”.

Alex also a lawyer focusing on outsourcing and technology transactions, including off-shoring, business process and assisted transformation outsourcing, information technology and network and systems and software procurement and integration and data protection.

Alex has led a number of projects which have been recognised by the FT’s Innovative Lawyer Awards and was shortlisted for the FT’s 2010 Innovative Lawyer of the Year award.

Alex is recognised for outsourcing and technology transactions in Chambers, Legal 500, Legal Experts and PLC’s Which Lawyer, with clients saying:

“first choice lawyer”

“I was impressed with the quality of his work and excellent industry acumen, which is spot-on.”

“impresses everyone he comes across”

“in big-ticket outsourcings you want a pretty robust contract to draw on, and that’s what Alex always delivers”

Linkin e-mail Website

Bio

Amanda Illing is the CEO of Hardwicke barristers’ chambers. Her role is to develop strategies to grow the business and to build long-lasting relationships with clients while ensuring Hardwicke is run in an ethical way. She takes responsibility for the career development of the barristers at Hardwicke, and her staff team. She is committed to meeting clients’ needs and providing solutions to engaging the right barrister for the right client/case, and working out fee structures to suit.

Amanda was previously the Private Secretary to the Director of Public Prosecutions and a caseworker in the Crown Prosecution Service, handling cases such as the appeal of the Birmingham Six, and the first corporate manslaughter prosecution following the sinking of the Herald of Free Enterprise. Amanda won the Silver Award for Inspirational Woman of the Year at the 2015 Citywealth Powerwomen Awards.

She also won the Eclipse Proclaim Modern Law Award 2013 (Non-Lawyer of the Year). Amanda is a Fellow of the Chartered Institute of Personnel and Development (CIPD). She is a trustee of the Public Law Project (PLP), and trustee of the London Legal Support Trust (LLST). Outside work, Amanda is a member of a group that is trying to save its local pub, to open it as a community pub.

Linkin e-mail Website

Bio

Mr AG Rao is result driven professional, with over 24 years of multi-domain experience in varied industries. He has impressive, fast track management career marked by demonstrated ability to build peak-performing teams to turnaround business SBUs, and achieved functional business objectives.

He is one of the valued members of senior management team, contributing to create pragmatic business strategies and implementation plans designed on Cost efficiency, Operational excellence and Risk-free operations.

Bio

Douglas Sperry Makepeace learned marketing from IBM, and the investment business from Merrill, Lynch. Sir John Templeton was Sperry’s first investor, seeding a fund of funds in 1989. In 2004, the JPMorgan Private Bank created funds for Sperry to advise, based on the record of that first fund. Sperry’s total assets grew to $500 million.

In 1991, Sperry sponsored a single-manager fund, and raised $40 million for the manager. The largest investors were Soros funds, Haussmann Holdings, and many early funds of funds.

Currently Mr. Makepeace advises several institutions on hedge fund investing. Their assets total about $10 billion. He also continues to represent managers that he admires, introducing them to investors he admires. He is registered with both the SEC and CFTC.

Why I spend so much time in the San Francisco Bay Area

In 2014, I read a book about the growing power of technology. This power is growing so fast that it will solve many of the world’s shortages in the next five to ten years. The result will be abundances, and Abundance is the title, by Diamandis. The future is being made in the Bay Area.

I’m working with several ventures that have a Stanford connection. Together we can rebuild education from the ground up, so people can learn at their own pace, in accord with human nature.

And I am working with several technology companies, like the ones in Abundance. Certainly, many ventures will need more capital over the next several years. Many excellent people have good ideas, and deserve to have investors.

Sperry Fund Management has been finding and evaluating and monitoring hedge fund managers for 25 years. Now Sperry Fund Investments is bringing excellent venture managers to investors.

Bio

Linkin Twitter e-mail Website

Bio

Ann Attridge is responsible for creating and developing Scotland’s first fully digital SQA qualification and building a team of talented designers and developers.

Awarded Approved Centre status by the SQA for the delivery of the National 4 ESOL course using Klik2learn’s e assessment system. Nominated for an Elton award by the British Council for ‘Excellence in Course Innovation.’ Responsible for operational and strategic business planning.

Linkin Website

Bio

Dr. Vivek Gupta

MBBS,MD, DM, FACC, FESC, FSCAI, FAPSIC, CICC, FSCI, FIEIC, FIC (France)

Dr. Vivek Gupta is a Skilled Senior Interventional Cardiologist, presently working with Indraprastha Apollo Hospitals, New Delhi and associated with Indo European Course on Revascularization IECR as Founder Scientific Chairman since its inception and also facilitating the Free Services to the poor heart patients through Charitable organization since 1996. He is also involved in heart research in collaboration with French and other European Cardiologist. He is recipient of various Fellowships including prestigious American College of Cardiology, European Society of Cardiology, Society of Cardiovascular Angiography and Interventions (SCAI, USA), Fellowship of Asian Pacific Society of Interventional Cardiology, Fellowship of Cardiological Society of India etc. Honored with Delhi Ratan award, Glory of India award, Best Citizen of India award, Leading Health Professional of world, Cambridge, UK, Mathur Vaish Samaaj Shiromani etc.

Dr. Vivek Gupta is Founder Course Chairman for International Cardiology teaching Course – Indo European Course on Revascularization (IECR) for young Interventional Cardiologist with objective for the improvement of healthcare of Indian Physicians and Cardiologist by enhancing the knowledge base of Physicians based in st Rural regions of Indian subcontinent. 1 IECR was held in Delhi nd (Jan 4-6, 2008), 2 IECR was held in London and Delhi (Nov – Dec rd 2008) and the 3 IECR was held in Paris (Nov 3-4, 2009) followed by th Indian Chapter in Delhi on Dec 20-21, 2009. The 4 IECR was organized in Amsterdam (August 24-26, 2010) in Academic Medical Centre with huge participation and record 13 Live Transmissions. It also had European Board of Cardiology accreditation and th Collaboration of American College of Cardiology. 5 IECR was held in th Rome on Nov 29 , 2011 with Japanese and European participation. th 6 IECR was successfully accomplished in Zurich on Nov 21-22, 2012 with live transmissions and lectures. IECR is also planning to educate the Doctors based in the Rural India for the enhancement of their knowledge with the aim of improving the healthcare of India. Dr Vivek Gupta and IECR has got special recognition and applause from world Cardiology community. Dr. Gupta is also, Founder Director of Indo-European Interventional Council (IEIC) providing Research and training for Cardiologist globally. Foreign medical Students from France and other European Countries join Dr. Gupta regularly. Dr. Gupta is often referred as the bridge between European and Indian Cardiologists.